var title_f3_38_3680="Contents: Hepatitis";
var content_f3_38_3680=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hepatitis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hepatitis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Autoimmune hepatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/32/27140\">",
"           Classification of autoimmune hepatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/44/35528\">",
"           Clinical manifestations and diagnosis of autoimmune hepatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/4/35911\">",
"           Definition and treatment of variants of autoimmune hepatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/4/31812\">",
"           Extrahepatic manifestations of autoimmune hepatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19590\">",
"           Pathogenesis of autoimmune hepatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42902\">",
"           Serologic markers of autoimmune hepatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/7/40058\">",
"           Treatment of autoimmune hepatitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug-induced hepatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/3/34871\">",
"           Halothane hepatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25642\">",
"           Hepatotoxicity due to herbal medications and dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/61/41943\">",
"           Isoniazid hepatotoxicity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis A virus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32980\">",
"           Atypical manifestations of hepatitis A virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/55/7033\">",
"           Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/38/1641\">",
"           Hepatitis A virus vaccination and postexposure prophylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/26/7591\">",
"           Overview of hepatitis A virus infection in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis B virus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/59/36792\">",
"           Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/22/37223\">",
"           Antiviral medications for the treatment of hepatitis B in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21045\">",
"           Characteristics of the hepatitis B virus and pathogenesis of infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30122\">",
"           Clinical manifestations and natural history of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6250\">",
"           Clinical significance and molecular characteristics of common hepatitis B virus variants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/52/36681\">",
"           Clinical significance of hepatitis B virus genotypes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12760\">",
"           Combination therapy for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/30/11752\">",
"           Entecavir in the treatment of chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/55/7033\">",
"           Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/31/4602\">",
"           Epidemiology, transmission, and prevention of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44020\">",
"           Evaluation of chronic hepatitis B virus infection in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/61/3033\">",
"           Hepatitis B and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/37/1625\">",
"           Hepatitis B virus infection in renal transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26009\">",
"           Hepatitis B virus reactivation associated with immunosuppression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31690\">",
"           Hepatitis B virus vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/31/23030\">",
"           Investigational treatments of chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/24/6538\">",
"           Lamivudine monotherapy for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15402\">",
"           Liver transplantation for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/55/23416\">",
"           Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/62/6119\">",
"           Monitoring the HIV-infected patient with chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/51/24378\">",
"           Overview of the management of hepatitis B and case examples",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/10/40104\">",
"           Prevention of hepatitis B virus infection in the HIV-infected adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44488\">",
"           Renal disease associated with hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/18/42279\">",
"           Serologic diagnosis of hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/60/14281\">",
"           Standard and pegylated interferon for chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/9/25750\">",
"           Telbivudine in the treatment of chronic hepatitis B virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/9/28822\">",
"           Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16185\">",
"           Treatment of hepatitis B in the HIV-infected patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis C virus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/30/15847\">",
"           Approach to patients with chronic hepatitis C virus infection and normal serum aminotransferases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/5/29780\">",
"           Characteristics of the hepatitis C virus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34040\">",
"           Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31530\">",
"           Clinical manifestations and natural history of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/7/18554\">",
"           Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38536\">",
"           Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1048\">",
"           Diagnosis of hepatitis C virus infection in patients on dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/7/2169\">",
"           Epidemiology and transmission of hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30218\">",
"           Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11848\">",
"           Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15498\">",
"           Extrahepatic manifestations of hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/56/4999\">",
"           Hepatitis C and transfusion: A 'lookback' primer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31289\">",
"           Hepatitis C virus infection and renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/24/31114\">",
"           Hepatitis C virus infection in patients on maintenance dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/30/39398\">",
"           Histologic scoring systems for chronic liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/30/38378\">",
"           Investigational therapies for hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/5/16474\">",
"           Liver transplantation for hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/55/23416\">",
"           Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/9/16538\">",
"           Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/23/41337\">",
"           Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/33/28184\">",
"           Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/59/35768\">",
"           Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/31/36345\">",
"           Monitoring the HIV-infected patient taking hepatitis C therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/62/24551\">",
"           Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Recognition and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/40/1674\">",
"           Neuropsychiatric side effects associated with interferon-alfa plus ribavirin therapy: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/45/43735\">",
"           Overview of the management of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/59/38841\">",
"           Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30421\">",
"           Porphyria cutanea tarda and hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/8/14474\">",
"           Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/58/40870\">",
"           Predictors of response to hepatitis C treatment in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/41/36505\">",
"           Principles of interferon therapy in liver disease and the induction of autoimmunity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3928\">",
"           Renal disease associated with hepatitis C virus after renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37353\">",
"           Renal disease associated with hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/21/27990\">",
"           Response-guided therapy for chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41849\">",
"           Screening for and diagnosis of chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/26/15785\">",
"           Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/38/18026\">",
"           Treatment of hepatitis C virus infection in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/52/36682\">",
"           Treatment of the mixed cryoglobulinemia syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/47/24314\">",
"           Treatment regimens for chronic hepatitis C virus genotype 1",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/37/600\">",
"           Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/19/26936\">",
"           Vertical transmission of hepatitis C virus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis D virus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/57/14230\">",
"           Diagnosis of hepatitis D virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/29/3543\">",
"           Hepatitis D virus reinfection following liver transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/11/15543\">",
"           Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22583\">",
"           Treatment and prevention of hepatitis D virus infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis E virus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/11/33976\">",
"           Hepatitis E virus infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis G virus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7557\">",
"           GB virus C (hepatitis G) infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transfusion-transmitted virus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1303\">",
"           TT and other anelloviruses",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F85150E683-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f3_38_3680=[""].join("\n");
var outline_f3_38_3680=null;
var title_f3_38_3681="Stool sample 6 with answer";
var content_f3_38_3681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schistosoma mansoni ovum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wet mount of stool (x400) shows ovum of Schistosoma mansoni.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3681=[""].join("\n");
var outline_f3_38_3681=null;
var title_f3_38_3682="Central bronchiectasis CT";
var content_f3_38_3682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central bronchiectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 301px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEtAV0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxbTrM3KM8pMVruALAZY+yjvW4waFo7W3WI3AG5EX7kQ/vN6tVW71ONLcQaeCXHDShcAD0QdvrXq/wV+H6Pbpr2uQhonO63hkX75/vHPagCz8Ovhut1FBqXiNXNj/rI7Vxte5Y/wAcn+z6LXsgACqiqqRqNqoowFHYAUEliWOPpQBz3oABS7eOv50opT1z2oAaV9CRS9AeMA80uOD3z6U5Vz96gBqKSc8bfWpQABgUU1Cd0uWyA3AwOOBxQA6kKglSeq8ilqC+vLWwtzPfXMNtCP45XCj9aAJ6K8+8bfEu30K3hfSrGTUfM5885SFR257/AIVwmqfEfxTdxQNb3drYtOxAghiDSIOxJbPFAHvlAIJxmvDIPiB4vOgG5WWykw/lCXyl3ZHGSPU1btfid4gsmaPU7SyvWjxvWMFGA9eOKAPaKK8zsPjDpE10kV7pt/Zoxx5hw6j06c4rstI8U6DrEJk0/VbaQKcEM+xh+BoA2qRucCnBWxuABB6EHNNGfagBRwKKbk7gARinc0AFFNdS8bKGKEjG4dR7inUAFHOTxx65oooAKToOOaXpSbR1wPTOKAFornPFXjPRfC7Rx6ncO1zJ92CBC7/iB0rhdd+MixXBTQ9IaeEEDz7ptm4nsFHNAHrwBPQUhwDgso/4EK+bPEPi7xLrUM8k+urapGQRa2reUWU9enJ7da525t7lorSfzL1IrgEK8lyxLkdcDNAH1DrXiDSNEKDVdQgtncEqjHLMPYCsOD4meD57hYV1uFXY4G9So/OvD7Z4zpdtdFme7spSgklfJx1yc9cVNd/ZpRvnS2lZyHEyH7wPO3FAH0lY39nqClrG7t7kDr5UgbFWcY618taNp1s+r3F7aXUumxLgpPFIUbpntXU6F8R/Eujukd40GtWG/aDIQkwX/e7n60Ae90Vxfh34l+G9akSBrttOvWOPs96uw59A3Q12pBGOOCMgg9aAImTHQcUz5d2Bg+lT0hUHmgCPrxmkbH8Q4708DrkY/rTcdec0ANPXn6CpbMkF8HHTimEH2qS1JBfGc8ZxQB85fCzwpc+M7tr7Uo0tdEtm2yeQNv2lx/APb1/KvoRFSONIoY1ihjAVEUcKKqaHpFpoOjWmk6am21tU2g92Pdj7k1dA56fnQAD608d/5U0dj60/GBigA9u/rSqDuznI9KAM8DpT+lACAY+tLQBk4HWuB8afEqw0WU2WkJHqep5IZVfEcR/2m7/QUAd5LLHBE000iRRIMtJIwVV+pPSuQ1r4i+GtGhXZdteszEBLJfM78nPTFeMeKrvWtZtVvtd1B7hHIKRIdsMfsAKxYpfLKtbpGs2MJkZBHfjpigD0zV/i9f3MLnQdLS2iDbTPdHeR6fKOK4cDUfFl2l1qVxPeSFirufmVAP7q+tZ1xI6sY3Vvs74/doMAMKYJUhWC5tvPikD7iY2wB+FAHR6nPHY6cLa/aXUjx5FuuUMAH94VgXN5c31+k9zErt5e1Gb5eOgFQTSbbeS5JdzdMSC7ZOR7/WtC+soba10uZZHuPOBWRkO7YT2xQAXkF2fJtEtJEFuu9jE+4k+tXtdtbi00+2udvnW16DGZXXHTsT2NZAaa0lAs/MtpHk2GVvvEVIJdReOe33u9lI5doxyrMO49DQBVgWNcuwZfKGORkv6Ctu+/sO18LLbhxqGqz/vXdRj7OB2B71RgWKeeC4u4J5LKIhZJIuDjGfzqDUTYy3CjS9OvbS1cja0+ST+PSgCzbyanplxbPHqt5bb4gyNFOcLn7uRniukt/HPjjTZJI3uUu4olB33EIIx67q5VrUsstzDKDG0iwqM/xfQ0lxLc+bLHf+YUjICxI2AzD1oA9JX4wajFastzoUJuwQAVlIRv8DXV+DPHsniG+jtLjRLm1Z1LG4Q74gR2J9a858K+AtU8TTrcX6vYaXJ85fP7xsdABXtfh3RLPw/piWVgpEa8szclj6mgDTooooAKKKKACmTMyQuyRmVgCQgIBb2p9FAHzxqYtNS8TahdlXhtY5y1zEeZkzwQO+RVzxh4e0jwro8cVlELyHUY/OivZ5MyRHI6fga9N8WfD/RfEczXLpJZX7MGe5tjhnP+0OhrmL74V37wIlv4lefyhtijuofl2+hIzQBwC3nhM+DTYzaJdxa8nzLcdd7Dod3oQelUbb7PcWFot68zNtIijAwEYnpn8K9Ch+GOrR6VqM17NYXmsAg2jKG2qB1HI9hivNL+9uVuGgvAY7qEFFjdfutnpigCvr2nSaVdW1hqEbJM8fnsp+bknj68YrV8LroK6ravrRiS2O63851xKOMZHoKx9StblGV9UjuDBIqne4OQD3Q96Li1jtoYXjZZ4p1zFNj0/hx2I70Aa2sW76dcn7SgvIUkK28kH3ZY+xOO9UIbWW5kv549jC1h8zyCfmYk4AHqRVXTdUvbWzntba5Zkm+8pXjj0NV7W+ljkyWyJPlcnnv1HtQBv3F5Z63odtFcaXEupRDYZUbII4wSP731q9pF34k8MwJcaHqc0dsrBTa3BLxse+Qen4Vgf2fcSQubSZvLk5jQNg5B65rV1XxHqF3oSWOqSBrpFCxnaFG339/egD0jwt8YrG6ulsvE1uNPnZtqXMJMkLn37r/KvVY3SWNJInSSNxuV0OVYeoPevkpTaQ2j3YXybu2YKQOUnB9+1bHhTx7rXhW6EkLJd6XNh2sGOAPUxn+E+1AH09TSDg/z71jeEvFGmeK9LW90qXOOJYH4khb0Yf1rboAjOcYxx6U6A4Z+nbvQwxk0RfKz/hQBCvbIzzTj1pF4p3uKAADGCf0pw5PseTSdDz0xT1GB70ALSOyojO7KiKCzMxwFA6kmlArx74zeLTcXH/CLaZI2CN17LGc/SL/H8qAM3x98SJtd8/TPDryW2mrkS3I4kn9l9F/nXnJkW3iiCxBJAOcHPmAnr9auTWqLaW81v5ryRx4uUZcbD9PSoYsJNFLGoaEHft6jI5H60Ab+lw2g0fXItUNwiNAptYnXBV81iJerJH5e6NpB8q+Z3b0+lPv9TvLq4mvJ5fM3sNyn8uavvPYW+j2ltFaxNc+eZpb5zkk9kA7ADvQBn3yzpK8cilYpTjZ1xjuKjj25AuJGbcuV4wwHfNWXuoPsIUwML158xkEk+X3Aqm5WFmW4hmSbfg5OQB/+qgDu9astO0z4f+HLe1jkuoL5JJhLIgzu68nPGKpeAbvT9M0nXtcuWQ3Ecf2WziYbvnOcnH5VJ4Y8TySaromjy2yNpcR8hI/vnc/Gfoc1duh4cttTvdK8M2cn2+0aSSaSVsoX7gD2oA5e41Ez6ANMmitjdb/Pa7dsHnsBVNC1rm5sbnfCAYpCoxhiOuPSn6/rF5q9zaJeWdnAkaBF8lcFh6k+tVoI2a4V4v3RWQBZAdyjPqO4oAlcRhUBuGUFi5K52kdRn3rX/tbW7XQrXTHu47jS7pWAt3QMeORyORnFQ6gZ7Wyj0JoVuZZ7gSq6AZlBPCr3r2H4e+CItEtUvtViWTV5VBcN8ywj+6B60AcToPwuuNX02yvpbybTY5cs1pLFlkHqOep969F8M+A9D0CNfKtzdXA5M1wdxJ9cdq6okk5PWkoAOgAAAA6AUUUUAFFFFABRRRQAUUUUAFFBGRjJH0ooABwQe9eH/FrwffWWsXXiDTADZz/PPhctE+Ov0OK9wpsiJLE8UqB43UqytyCDQB8zahqi+I7Ww/ty4uFkt4CsQjX92WHTioPD+l/brMWkr20SiTfHE8wEkR9cHrW78T/CLeFbyzvLR3fTp3dQB/yyYnIH61zN7bJbWVvPZwSPG0bGS6kAzv8AQUAVNa0rUNCZba9t5Y3kOY5iP3Tg9Pm6ZpqW9pDp7lJmmuSdnCfu0HfmrWl6rqT+GrrSJLiS5tZHEm2b5hH7oTytRQ20dxBp1nJOLGG6cr58n3OO3r+NAEOsXEV3dxf2dHPHHBEItqtlR6mqV1JLdXRLXEWVhADuMZX0+tbepaJZwalqEOi6vG9vBbhzNIdokP8AEB+OKwboozKSn3o1O516H0AoAekd5cny7aCS4hiQGRY1zgf3iPT3rRNo2l6Ibm+tmJuxstV6bFHViaZ4b1KXTNUiuI5Gtw48mYf89Ebsas6pdXF9qLWMcu+3hHlQqfugZ7+nrQBU0++1Xw/dxavo8ps7iYYRgflkAPRl75r6M+G/jSHxhpLNIqQarbYW6tweh/vL7H9K+b4IVutTkE2GSCNgkiE7FI7/AI0aJqV74d1az1zSQwaByrEHImX+JD68UAfX1NjOxmGDjjHeqHh/WbPX9GtdU05w9tcLuHqp7qfcHitONsFgR9KAK6g556U4dueKYihSTzluvPHHtUi9aABRkn0p/ejpSjkgUAch8T/FA8MeG2eBwNRuz5Fr/sk9X/Ac14HcWsenG2ksL5ri5nbcZOuSe5z610HxL1ePxH4yunhkzbaePssK7uHIPzEfjmuUWNraWNVaNjIAQrD7nuaANTTIrvV9XuIJLlbSXyysjO2A2BnB9aoxwrFHNHBKJGhcjev3W/Cmzwyy3cytLEbkncxU/LJn0qC0lNnPNDNmJX4bI4z249KALr2ltFosV3JOrTNJjyI2y6e5qrcRyiCFJLYxxLlt7oQDn37U2W3ATKgBjkDb/EetdFq/iC41HQrW0Q5tsBZ1Jw7MOn4UAc5bOz3KSxiTzox+8wOw7r9Ke0TzST+W88q4yzNyxHXP5VM6zF2VGaIyqOF+UMvpmnWkFwbab7GjqkK7ZCq87W7k0AbXhWxks7fWdfnjfZpdsI4THgAySDCt+FY3gxbjbq2pHHlW9sfPZ2O52c8BfUk5ru/A9jFeeHNY0DV7qSOzuALhpYuWjx0J9q6j4a+GNPtLaS0sJP7T02SYTSXbFcMy/dTb17k/hQB5T/YiWWo2trLcBrt4RPMki7RGpGQufWppJv7O0VojDblJJAFfJLqe2PrWl481HSrzxlqslpaTXCbhHO5faF28ZTFR+G7Z5PFOiWtpbRXMElysgWUbgEHJJ+lAHpPwu8GnS4P7Z1hN+qXPzRxuM/Zk7Af7Rr0KlY5YkUlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRQCCcA01GyCT0Bx9aAOc+I2ivr3g++toMC6jXzoCf7y9ufWvncwwy6Is8dwWNvP5c0ZclQ7fxYHbmvquVEkieOVQ0bqVZT0IPauEu5fCPgRJbS0s4GnuMFrRMSMx7Fgc0AeG2MUbK0dxdn7NdZDXO3KqBzkD8KzJI2v5IoLS1lvFy21kUklf72O1dHrD2xsLwQQSW8O7cIwmNgJ5A/wrM0yS6hvkt7S9ey3gRC4Py43EZ+nFAEN1YXMCSXEdlKLfKr5sqfKvr7GtKHSri70i5vyzSRxYRMKDj8K6PU4LfT/AAPf6ONaW6uLecTREk7JE/iHJ65qXQdO1DSfA8ms6jJ/xJ5pVnliwdzp0AUUAc7p3hpVnt7rUfkhILgSA/LjuRU+n6FY3kWoalqeuQ6fpBQtF5a4kmcdgp5rUtrr+1dTu7jT1ulsfKSVBK2WhX+6fUVyniX/AEnLM63F40vmSOTxGvZR2FAFaW/jg8LT6fZK4F1MC7sQGKjp9Ko7Ps1uUuZ5YmTB8kjj8AO5pJbG8tY4zLbuiMvmAkdvX3qZ0KKLmdRLdTY8lCeAB3oA9R+AuvrZajceGLk7Eul+1Wyk8I/8SD1yMGvcRkAbVLV8hQXV5pd1p+pWjxm7tpfOXacE46r9MZr6v8Maxb+IdEtNVsGV4blA2M/dboyn3ByKALI609B3qMc/jU1ABWJ4212Lw34Xv9TlwWjQrGp/ic8AVt14Z8c9eGoa9b6BA7NbWY33CryGlYZAP0GD+NAHBQ2738cT24LyTZLrt6HqTmtC80qSLSIr9JIARN5RG8Et6celZ1s722k3NtFcNBHIcMAmGY9xmoLmxFvFaBW8rf0ck8knjmgCNEMl3+9XJBJUoKvXOoNc/aRcK0lwyrHG6jGxfcd63PCPhq3uruK48Q6pHY2NvL5e0Eb5iO30NXfij4Qs/DN5Yajossj6feblI37vLbgg57g0Acvpkd5FBPdwn/R4sL5hPIJ/rUSlJlZsFZmAVixPzD1BrSsNSSMJ9phlazZ8u8SYBYDgntWV5glmZkt1RSSTtJPfjIoAuJBPKPKigmkZsCIIMj8K0fO1fSNKuIC8MC3kqxzoFDPtHTntU+kWVzcW8gk1ltPm2E26sM+YR29qj0rULmPxLoVje+QLV7tHdyB8w3c5oA6D4c6fBcXmqm5v2tbOGJQrSYTeT2OeoFeraFoVroXhm4tdJjVZJYpJTIP+WjlThs15T8fRCniHR/JlUW88JDLE3BIYYJxW/wDDDXbi2stQ0DUJPPmigee1cPv3Dbymfy4oA81g0lorg/aLxYVVDJcTI2/OGO5T9a9q+HXhqysEfWolcvdoBbLIOYoT2+p6141o8CXWn3pnt3t7qeaONd8Z/eZk5UflX00kaQxpFGAqRqEUDsAMUALQfbignHU0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABOOTS01gSOMZ96WgAPTpnHOK+XvEt+ZvFWq6hcO0JkuTEzgE7QOOPpX0T4w1iLQfDV/qU3SFPlA6sx6Cvl2x8WyQXTtf2UF+PN8xhKCGUE5wD3oA1onOqLLZwfvo4rctLMzfMzdV49aNRg02zitktrad70gLO/mbjnqAF/Cuk8Y+O9NWC3Oi+HBBa3MYZLofu3Jx8y4x2NcrHbvrLSy6dDCbl5Fjbe2C2e+TQBe0K0fVvMiuIy4s0LCNyFzk9M+/8ASu9+MTyj4c6F9mEllFHKm+2IwxAXGMd/WvM9Qje1+HepJcK0V3/ai2+//ZC84P1NdN4O1rX/ABZodjoGpWYl02GTYNXkBCqB/CWPBIHHHtQBzVld7L60+yXjkxxiSdEG4Mc8IwHX0q545v1vfEc4WxSySVFDxICqg/3jWl8T9RsPCmt22ieELNIJUjAu7hU3NOzfdAPc+tY3jr+0tN1tIdSXF39ljmZsZIBHQ+4oAd4gtL3TINOiuJTd+dF+6lzwAexFYQcTXUkcqs8jfJE/TYwxgfSpZ5L/AMUajBaxQzS3yRARmOMts2jJJAzVe1W5eWRGErEgoVkG1gwOM47UAaWo+G9VsIreS/WOO6mbITzRhE/vH61Z8KfEy/8Ahyb6wjsmvbG5kE0KE48psYfHsflNT6zZapPDZ/apVBSPaxR8kKOhb3rk7qJI5isri4H8LMAfrigD7JjyRUlMiHHQfhT6AKWt6lFo+j3upXBAitYmkOe57D88V8vJZ6hf3rX19HOJLqU3EsoUn73IBPbHT8K9f+OusNb6TYaRA3z3UnmzAdRGo/qSPyrym58RXs9n9nzNFGqhSQBtcH270AS2+pWsHhd9IEBe7lnM4uXwdij+Ed6y0uZbe7tmQrL5PzIkozz9O9C2F1PE93FaTLbR/flUcfl1qzrmk3dnpmm3Nwm20vY98U/Yueqk0AQWUV7cM96lrJcJBJ9okJ4APfArcZHe4fTmM9zpWoYuLGX7wikxyp9KzY7+S2sLGGzc5WNo5xuwzse9VdM1W9sVmNrcMgyf3TDjPrQBraaGnsNU0q5kUrGu+KIjaTIOuKy7eRbe8hlOVcKCQR1Zex9qW/guba4LXkbxSToJEL8bs96JUiNvF5b7psEOo4GB05oAn1TWLrV9Qa9vkiknuGAAjTbGoH8K+hrYvrjwddaPtsLW50/VbYBwHJYtJkbuf7uM/pWDp8E9xfWlpbKjS3Eqqod9qgk9TVnxBYT2fiG4s9QaKSeKUI7Q/dx25oA64ag+mfB7T9Rt7GKe6a9Mdw9yN7L16enQcUvgm9gl8Qafq+m2cUKMkwlhkf7siqDwfQ1QsLefU9H1vRbR1jWTZPHHI2dzL/dPrWbcWo0IaBpj/NfGXzptp7txt/KgBut6heX2/U5rk2rCXz1s4/uqyt1XivpHTrg3enWlycgzQpIQfdQf614It1p0Nxei8tmkmtgURV+5KWOR+WK9t8JalFq3huxvIFCo0e3YP4SvGP0oA1qKKKACiiigAooooAKKKKACiiigAooooAKKKKAA0UdaKAMPxpaadqPhbVLbWFmayEJkl8oHeAOcr714/pfhTw23h9p7W1lvJ9QRl0+TUD5RLjqQPY171NvMMgiK+YVIXcMjPuK8O8XeINA0aWy0zWbe/vNUsb77Y7oQiw7jkgexB6CgDL1Hw3q+q6NDbs6Wt1p52iK6dVR+2VPau+s/AOnaH8PWh1GZIr1VFzPes3CyegP93tXL+O/DPhy9vrOVNavIvtsZuniLllKn7uD2+nNRzWPinxFpsuj2rSXlpDHta2uXC4A+7lh19qAMTXLO21XS20OO4e3niuPtCbvuyggZYe1LJPps1vaeHrG9mh0PTxlgxI+03R5ycc4FdJYfDrXNc/sqfVFh0lraIxs4O5+OANvf86xfEPw5l8IRC/u9UFzDI/liUqEC56ZGetAHO60JLQRJcSLJNCRIrMfmX3z3AqHU9K1zVLx/EF5crc+coLymQEFfQD19qJHitZXEkazmPb5eWzlc859q7efQ7LxDa3i6Jdx2GnWsaF4mbakczD7uTQBwnh3UdU0SS5vtMvWtzIfKWUKDx361Wt51bUYPMuJftF3Li4uH7Enr09TVnxDA8EMEN7L5d7aMYvJXgOvZh0GazQZPMUs6L5ZChf7zdRz3oAn1G7ubW8ms5pwI4XMTop5Zc9c+pzWRcX8TSsEtlCKcAO+CPy68Yq3qcgu7oyzx4mk/1pP8RHtWVqcLbo3m3ksCQkeBtXPGfrQB9uIMKBQBllx3PJpaVPvr9aAPnTx9qUt/4y1ybUrWeKO3ItoAD/Cvf8c1y+pPbNbweUSyn+6cFT6V3sWi3V/rWtLfR3LTzXchSM8g4IwAfTGKpano/hpGlF/FdW0qkB/sr7l3f0oAw4b20h8MX1rYGcalMVHmvKdpXAyAPSteO3WXwFpsV/exvOhZ4Id2QiepB6Gsa/07wsHcW+sXFrIrfIJkJBHqParZ8IzPo13qFv4i0y8WBdwjgP71hjkYoA5u4tyNskciuG5BU8j2PvWr4evLDTmu5tRga+uGTy4Yug5zyfp1qjZx6X/ZGqSXc5E4jT7LGR958jP6Zp+l3cFpBb3hGLmOXdDHJwJFxzuoAbcalqN5Hi7kLp91HdcjK9ACfQGoJHSOGZZW3ZCsWHGD6iuiS7XxNe2lheiOw01YppCsK7UEnUc9zWDHBlYY5ZVbAAYOMkDtmgCULl2lKxkIqsJFGCpxxzUUImkmJi8xpnU/ffcJPf61cW3RZ540ljkCjhg3yv8A4YplgbmJzcxAZxsLKA3/AOqgDT+wx2l14fggkuP7SKs0rAkbG7CsvVDdWd/PNfKYroybv3pyxIPUV0nhG01XxTq8kOnyiBok87zJTuWBs4B9z7VBquiXcHjez0TWLpru5e5jeSZoyAyZySPagDa1Kxt7nw9BruowXUNncqsaJHHhy/IP0zivS/hi1sPCVvb2cckccDFSsg+YZOefzrZ8R2ttc6DeW9wQlsIuGUZ8sDoR9K5P4aS3r3+o+ZdJd6c0SfZ5UYEEjjt0NAHe0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIyhipOflORyRzS5oooA53xR4ts/DMqf2nFItu0ZcTAjBP8AdA7mvKfijrXgm9v7Ke60e7utSubdZJGhm8rYpAwH6gnHtXVfFHw5oaw/2xr2o3FvbvdKZizNI5UAARwr0AOMnjvXmHiTQLXxHq0994O1G31CFgFWydvKuIwB6H71ADtatrbxDo0Fx4NN8lpbRlL2O9fJhC8g59OK774eeO9H0XwVHLrEtzHbiYQx3kqbmuz3Ix2X39a5zwLYtpPhTX7K6vrODSblCmoX8hO6CTGBGg/iNZvxT0uOx0Hw3/wjy/bvDEcB2XkbFgZM87sfdzQB6nonxKsfEd9qOlaT+51VUY2TS8pOccH2+leQeK7XxNqGvJp/iW8k1DUlAlNkjYRSf7oHHTHNSfB+0tkfUPEtyk6roYEsTDpKWyNhrq4r2DW9Zu/EkUH2W8nhIZJJs5KjACntxigCDwf8ObW4giutcvFspJnxBFK4DufTrVDXPBni/wAQX174btLG303R7SUzLdEFUnP8JLdWP8qxLZpvEN7Y2eoWb31zb3P+iHz9pDk/dz6V6Xf/ABRudDsJLO50k3WtW0phaKOX5Ae3uaAOSu18Ra1f29p4i0Kwu9LgVLaaSywZkxx5gPXI64rn7nTLTSdQVobtdUsFneNJGj8srgZ2sD3967vTZobWyvvEurWSwX7Ir3Aicr85I6oPT1riPFPiODXYpYPMlMm7ehYY/X/GgChNfQX+kz/bbOKPUd2fMU7S0eTjFYUGjanqZZ9PjBiT5eW5zWpJouo3Vp9rt7GW6twqqzKoLL9MVWhaKwlmV0ueWwCTszj2H1oA+v6bNIIYJJSMiNGfHrgZpxOKQorK6yDKspDD2xQB4DZeK/FOtQztYXDRsZXaVoo8lFBP49q52fU52iu0u9sb3AI3Fdgf3IPrXoXwpm0hRqzNBbW9xbyyCOZnAIUsRjPc+1cr4i1O51ASbbGxubeymKCbeA785PFAHK2ZsJtUsl1BpEgBVSwGdg6ce1Q3VvBp+o3L2iS/Zg7Ksx4JU9M+xrqra58HR2MUuv2V41w8vmRwwDb5i/3SehGaz/FMdmupK+g3D/YLmNS0MxDGJfrntQBz9xHCxiHMQjXazuMqWPcVLP5Zj2+bKcgLgr1x/Sr2nw2Z1e3FlBJe7g4eKQH52AOOKbpen3WrtcfYj5ly65n3AKLfnpk9KAKzS3LQ7GVksoT+7jMnRv71bnheO01LUli1OSR55AyqrpkYI+9n0FV5tAlitfNS9t2ijGLhlYSHdnjgc4/Ctc6eNBmur2XV41jjjjiFxFFuK71B24H86AMK3tPJ1F7G4lhjhDsHlH3fl6H8a3/A3h9/Fmq6lHDPDZtbRqyryQ4J4JHX8azL7Q531COHT911PKF/dv8Af+b+97HPSt2LUJfhv4iilsYo9RluIVjvkLgMnQlRjoQaAO48KaLN8OdG1vUtWD37NICXtzn90O+D0PrUC+KvCXjnUorOB7m11mWF4bWeSIjBIzjI47dKtWXj/RfGN43h0QXVtHqNu8SzS44kx93APXr+VeIa1p1z4U1a5sbxxBfWThoZl4LDqkin8KAOvPivxLawP4aja3hitWa1mXaS55OfmPr1/Gm+C9UTwp4ks/Id1t5JRb3UZ7hu4HtUni57m+tfDGrTQB9R1K0IujCuDIVbCv8AXFZuu2ktvPElwyJIUWSKYsCAeozigD6WIwT3pKwPAusNrnhq2uZuLhf3cnPcd/xrfoAKKO5PNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFUdenmtdEv7m0Cm4hgaSPcpYZA9B1oA8M+P95dz+K4LOcsthaQCSNDwrs3U+57fhXmenIRqdpNbOIrlZA5AbAUZ6Cu9+Is114r03RvFEaMY1tvLu0VSFjYE/MAexrn/h1Bp7apcahrcLPodnC7TMOMsQdqg+vSgDr9S02Lxno09j4eWOK7sZ/MmhaUJFMp7qTxkGsrTfFOq/DrQ5NGhlsZpvtJmnhc+agQj7oPTmtv4daR9kvNR1lJbZNGP7mJmlzuB7H8KyvHVt4UtDPcawl295Ku62itiFRj2LEnn8KANrUNYvL/w9aDULm3sbqdTc2+nW0eAyHj5lHU+lcVqBi07eJri73W6bxGBnBPUE9qZoviGY2pjgtPPuYgGLztlowOyn0rb1a2aXSbDVNNUTW14SbuIRkhGXj71AHN2i/abRLmVhab33wyRHGQOx7itHTNfk029/tXTo7WS4R95dxls/3sdzVfVobj+zJLmaaPzZJVht4FGFcdyT2xTbG0guILYWl2i3wlP7nbw4HYN0zQA3VtZ1HV9Umv7m5d5LpgXUDYir9KuWFxpy6pDb30f9oW02Y7dI4yrCQ8Abumc1RRwb6RNQhmjV8xmHoQexB/rWb5c9xIba0Z9ykCMZJZMH72e1AHeQeJYPDOmzeHpIJoNRjcgEjDRk9sjg9q5WHQ/FPiGNr7SLFryHzGjZoF4DA9/zqxc+X9ljimPn32CZJpOfMP1611ukWmr+D/Dun3EGtvp7aruuHtiA4TGAMH3BoA9/pUGWAPQ8U1TkZpd6xgu5CqoLEnoAKAPlqS1D6hqTafbPFaRXUjFS3JAY9PU5zW3pnhO//tmwebT72PTblfNefGNgPdq2mvtK0uxvrx5oLgXczsqqMEZY4xzVK4+IElp4bTw+s7rJOHDXEzFioPIUH8aAIvEzrpdleeGdd0tnuEZrjSr5CDgH1PpXCQ6jkxogBiYGMhU53DufWuq0GwvJkm8ReIlu30y1YW7pKGBY4AGM9h6iquozabp2g/YLN45tRupDdeeq5WNOyDpz9KAMnSb+40u+i1i2lSK7t2DRkrlSf7pHvXrfhjx14T12G5h1yxg0jUrtfLuCUPlz8cEMP6141p7JPPDG8e7dIPMUdM5xz6V30HwzeCNL/wAV6jYabokLb/8AW73dSRwT05oA5HXvDWr+CtUiv4ZILq0EhkhuLUmaLqcK+OnBHWui0aaXxl4G8Ti80lpr+Bknhe1Hlbz/AHeeDjHSq39t6xJql/eeAraOPw/bTrH9nChkl46uG9cGu1j8QXuqaWYBaxWMg/ezW9vgKhHfI9aAOWu9Qt9L8JWSxCNfE0yAXDMx8yBBwuP9ojFc1CQF2JMWeZd0srnkv/tE96t6houoS6nc3T2reYq+Z8w3BkPOd3c1hSrFNIDysWCxRj1PpQBraXeGxihmjtZTfhy8lwo3lB2wB0PvXbaT430/WLWE+L9Bi1e5hBRLuJRu2+jA96wvhZrtt4c8QM2rKPsdyPKlkYbhCexOe1eqa/4B0LxBazX2hlYLuYb0ks5QI5T1G4en0xQB5zrGuS+K9espNMtnhitWW1tbWFcsAe59utYaWFxLqM1jqUDs0E0iJCW2lyGPGegFb994mi8Di40nwzbW0+r4xf6k3JD91QdsZqLTfD9pf+GRfXerItxdbjFvlxIHJ7+poA7f4HXUSabqOnlsTibzVXr8uMcHvXpoNfPej6rL4a8V6bb8RQW5Eb4XIIPUlh619BRSLLEkiHKMMg0AOooooAKKKKACiiigAooooAKKKKACiiigAqtf3Agh2o6LcTZjgDqWVnI4Bx2qa4Li3lMSb5AhKpnG444Fea/D3Wdf8Q3+t2GvG9tlQbreXyQjwHJBQEjGeOvNAGx4e02YNHD4i1axvNShLMbO0ACIDzsK+g96w/H1nN4o8MS6V4YbSnvYJ0aewiIBUem7gEiqcN94U8DapfjQnuNW1tkdrkyS7iT6Fsdc9hWj8KvB8Oi6bPqdzMIdX1ePzVRsD7ODyAPWgDiviBeRaf4c8O+ELu/hbVICDfG2GFiJHAJHU81z/iPw9p1poMNjfSFXhbzVQqWkYHvyelS6vaaP4R1if7ZqUet+JxIZGLL+4hJOcsc5LVTvtSn1i3ea/aOe8lJBnQH507AAdDQBhQgy3DWdjHcI7DDOUJ3KOevY16j8O7saDbta61dNbwXCMixLhhECPvmuWjk1Yrbx+W0FvEoRpJsR4Hqe54o11tJ+1Qi11XzYEURsoQ5kPcZz0oAba2Fpd3yWsupldDSV2E8qncwyRkEd61L/AEzQ2hW08Pyqk9mQ9ukr7ROCecNXPzah4fh0tbGzjvmDy+ZNJ2PooHbFZ0Z0VIhJCt+fmx8/VT7UANlQ3VzcNc+cBE33WYcN6fStfR7eCwvtOh1OdIrO9XzJXikG/b6E9qrpf6UlibdtKlZwS0kjyHnPT8KgfUmjWLy9Pt5Ch/dtIm4Z9M0AdFqGs+HNRHlWukFPsW8JPISTJEPUDvW1pnjXwlf+HdOTxhcr58O/7NHDGSI4iQAp9+K4278SXckhke0sYiowdsftyAR1rn7vVHLKo02yQAZwMk8+v6UAfZg6VR14MdB1MIoZjay4BOM/IavDoOMVkeL2ceFdY8k4k+ySEdv4aAPBLPwbqU/hoXMkNlHawKGeRpvnxnsPxqfSteuLa60rzdE02XR4pvKFzNDl2b1JpW8LapY6HDeXeoRWWkzWQeSZnz83UR7fU+1YM+oxN4St9OEsvy3PmBXGQFOM8fyoA9Ck8WXc+oanJ4ovLRdJkbytMhCfuyR1JHU8eprhfEfiDQtS1lG0qxdYLaAJapt2AsDycDtVrx29veLpcemEGK1hCKjp88rHln46dcVzckTxSabZJZrFeyAy73OHKnoD7CgDqbO407VNP1K0t9MW1iVxc3MpJDKo7E+lJ47+y3S6KU0ieOyng/0VGuSyMB1YD1PvWjc6VY6RDcaZFeIs+q2P2iXUM/uwgwRFj3PevPTcgLFamWS3hjOIdzE+X64PoetAG/p180FlPBAtvZ2kYzJDkgyn655atjVEh03UdMa41kWui3duj3VrbgNKFxyM9ea45ik9orzFWlifaY1XIdf7596gitnafBMzMT/dOXH936UAddB4nW2nt49Jad9Ns3byknbJdD2b1rG1a6j1Ay3LWX2NTjaVOAx/+vUUEd2kylLN38rJLFPlAPt3NT22lazqkrxw6XfTs658vBGB6igDU0rSodMns73Wopbqxu/9XHEPMeY4xggd/rXc+G/CmqaalzqdxI+hRxRy/YrVZiWkYqcbx0HTpXR/CHwjceGdAMuqf8hC6bzDEefs47KPf1rY+IGltqXh+ZopGS5gHmxFTg5HagD5cj8wyyNLl52c7w3JLZ5yfrmtqG5jnRFWIPJB8yhlxsH8RFdCdO0y+uYZtXR7MSoS1xbuCQw65X8Ko6Fo0WqapLCuqQrbRqzecwwZAPurjtQBoySeHP8AhFL+TTbmeO8usIEm5PH3sema9S+EetSar4bWGcq0loBGeefxrxlrK9uWXT7bT2vZ0yxW2TfuY9yfavW/g14c1LRNK1C41iIwXN5KCkLfeRVGMn0zQB6HRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFTVbtrGwluUQyNGMiMdWPoPeud0S81CB1mc3MlsyvNdyX2FZHwNiIBgHFdPdqjxhHbBJ+UZ+8fSsHxFpf9u2Mun3eqPp06ss0T27BXXHfnqKAOR+Gmv2niKTULXWNOsI74TySxrFbgM65Oc55zXCeL/Eeqp4nvLIQ3KzreBLeLb0XOAD6ZFd5pF3pHh7XGj1K4W/a3zIuoKBvDEcjjrmue1r4qNceLwdGsIkWJPLWW7H+sbscduelAEniPw9pFjpEL+IjZWc08hW5eXmWUkZATHPHrXEQeILXS82/hK1RBvybu6jLug9Rk4H5Vm6k17f6peX99At5eTM0nmSbiqH0UU7TrxVhupror5/lgwqqcBuh3fSgCjvl1PUpDJcTTXTncu5ztYHr1OM1FBpbSXklsrt9tijaWbdkbFH9amuLdblIpY3aNAdzKgwS2R+ddH4nIvfEENjFPHcSNaIrNGuDkqOCB1NAGHZ6dDfRRXVncEWIiHmORho3A+7juTVZTKJJD84Eb7QWHzD0yOh96u2qWCadJphuLm1uBMSkYQ7T6s309qqalIYbyS3a5EsS/OrBid3vQBfMLLa2885N1PdbkigiIClv9odqoCTyiYWwkseQ3zbgG9B71e8NwrHpupa7ewyNBbp5NvhTteVjgAH2qDTri5sbS40vUbSD7PduJHZVDOnBIwe3WgBrQW0mkKomYagx3NtPyxY7Y7k5rDu2X7SzCUea4DOCduD6cfSt21iWyezlu4pHjeUogUcuOzccVZ+I9p/Z1/ZfYIpUglg37okA3nPOfegD6xBwcZGO1ch8V7kWngDWCT80qpCue+51GK6/BPpXmPx8a5OgaLFE8iwS36+aqHHmfK21D6jPP4CgDye7vrsxS2m0usMKnyGJcEDGCFHTqaPEWjnTLqwtppFuJ7mFJgkfQFugpY9Q1LStcmlihSG4jQwtvGVAbqPrxWdDDPc3UksEkuyM/PPKeI8enrQBueI4brw3qGkPFKkojQSbDwVDfeXFSeJor3xF4lWfQ9LubzEexJDERwR6+1VtZ1+K+WNbSBWki2h7idhukPfA7is+TXtZkuLi+h1W7gEY4+z5REHQLigCbzrHTra7t9Tjlvbt4xDiNwqx46jPfpVBb22iWP7Np1uTIdpEpByfeo1YXrzPJCZ5XJLSKeAPXH9aZGiJbDMyMkrnen9wepoAs2Wq3s5uhE0cYiBY7UGMDsKdb6pqv2eN4ZJUSUc/IAfbBpNMufsU0Mr2cl1aEkMUyoPt9KfMsk96XkUQDooz8qKOQPrQBKtzdgEG8n8wEs6E/MfUY9K2rGXUdRD3WkX15BHHGOGl2tI3oKxpUiRg5syJZCHWRwefYD0q9plpdajcKIy8rgbjGDwFH90UAev/AAt1O9UNpGrSPPcbDOkztk4yPl+vNegOocFWXcp6g14/8F0tpvEmp3M8r/b1i8uKJjxsyM49xXsNAGVL4b0SZWWTSLJg3X90M/gfxNclJ8JtE+3pKl1qENoJC7WiyYVvbPUD6Vo/F2fUbTwHf3Ok3L20sLI0rocN5WcMAex6V4XYeMvE2lQeVY6xcJG58wCb94T9M0Aeg+MvG2veGfEsmj6Rp9lYWSov2dXiB8xe7Z6f4V1vwv8AGlx4us70X1pHBc2bKrPEco+R+hrkfhzq0Xj+31DRPGGLu6X9/FIThwO+z+7j0r0jwZ4VtPCmmS2diZZfNmMrySD5m9B+AoA3aKDxR09aACiiigAooooAKKKKACgsBjJAycDJ6mig47+tABRRRQAwssXmySsqIBuaRiAAvufQf1ryHxb418Fa9q72epW995VqdiatbHARvbByVz7EV6T4w0T/AISPw1f6SLh7drlMLKvZgcjPselfLF1YX1hdzabcWVylzG5jKCJju5wSBjkHGRQB6F4p8Jv4Zit9UimS906dgPty9kbkbgOAeeorjtZ0ux07VSyyz3EBGTIOHBxnbjuDXtvwl0rVl8EGy8TRj7E4ZIbaZfnEef4s9PpVWf4Q6VdXMlxd6nqDyFtybCFVPQY78cUAeEWU2yU3FxBI9m0uWAO0kdKmhd5Yw1tE6QSEhVdhuC133xQ8M3nhy4t/7MleTRiihI2I3xsvU5965xtW0iws9SSx0KSAz7Ut7ueYvIjfxMvagCPxBptpokGm2qSiW/8ALNxLKo+TJ+6vPoKyXuL2G5a9hVfOG2RnxtHp97+lMZyLqWe6kae5dRwxzu4649aQyebE6ljNDwWAOc+wHrQA69vGvdSE11cmaRFBQKoHXrz3B9aitmeVJIY42RwfMIVPlZB3q3qupTXum2UbJBGukRBIrcLiQg9Sx71u38a6T4bW2vwl2NaUSwNFw9qvpx1FAGJo39qX3hbWBFPHFptpOkzRyMFBJ9B3PtXS6NpnhCDQLceLfEDJNHuma2turBhx05z7VwdzG+pXMdlbxTTrF/BFk7vfj0qXU9MLNN5sQCoFQsPpwPWgC9Z33n6hPdaZKqWERJgWc87B2PoTWfrerarqV60kt6zxDiJWGAi+grV8Gafa3k1rpkjSiWQSsCBzwBgAfXNR6d4M1vWIC9hbOREzRuWcA5B7jNAH1uM5PpXnfxzRl8J2NwmQLe/jcsP4eCM/rXovtVDXrSyvtHvINVh86x2eZKnqF+b+lAHzZfK0k0moa4rLDM3zDkPMOgwO31qhL++mNuGEWnofkJbAVcfxeprS1ydte1GW5tZ1ijc7YY5jxHGOBzVO3tIbTWFjvWjmtIk5xzE/vn1oAzZBI1hGfse6J5cx3BUjI6YB7CtnwobaLRtesbuSC2N2m0XM+WUdwuPf1qTXdfaWW0soWEdnbITApUYIP4dK5y4aF7FZdjyXYJWVX4VRnggd6ANPwxdXOjavb6jJZLfWlsjK8RACFCCD/PNP0230/V9bs7XSvK0uScSPIbhsqTgkAH0PSpvCGlJqTaibq8it5oLfzYQzFFb1X0yaxJg06SyEQ+YhxuJ4B7YIoAsQzXbArLPIDGzK3y4RMHHFOVZZTOiOXiXDMAPvg9CKlFu4iha3k8wSRhmUnIZuhA9algjUBDOBtdtjYOCDgcACgDU06803+xzpniAO7LOJEnRiXhUfwg45zUmhakmneIZpLBlSymlIUFD5hh7j2NY90kVoJJbJzLGi+b5Lgbo8+vrWr4VuBczqhtgZJ0IQScBTjP3qAOp8JyafefFC1n0yWeOKWV5IF6DbsbcD+Ne4nqa8F8GTTaH480tNZgayD5ji3gMZA4IGCOgziveiMEj0oAy/E+nf2v4d1HTsZ+0wtGPr2r5ttPBPiaS9Wyi0e6MsbbWkOAp99x7V9S0pY+p/OgDyLwn4Gl8GTN4l167jU2UTlLa2UsWJGME9/piuZnvtUvoC1/r19GJ5PNELSbNysfu8dODXuWv6ha6VpU13etEERSVWQj5j6AGvnTXNa+06peXN3Anl3A3AIudw7YPagD0u++Ic50+O1020hQxgRTTPPkquMZUY6+5rV8LX17N4WvEjuL24ulZhHKu1nUYyDk4rxzRYozp6PFhNyOwZ1549+9dB4U8ayeF7m1ZB52mTH/SEUc57sCfSgDrtO8eXtxYGKzkWe5hcRtJLCfmPfPpWzpPj1JtUGn6pZPZz8jc33TjuD3Fed6hffZ/EN3Ppm57Cb/SQFHBDc49u9amlraa/Jaw3gma+hDSQqvO9T2BoA9noqGyjaKyt433bkjCnd14HepqACmuxUpiN33MFO3Hy+5yen+NOooAKR13KRnB6g+hpaKAAdOeDRRRQAVwnxB+I1l4SvYrNLA6hqbruKbggjXsS2CfwrvK+dfjjoV1p3jGTVcO9rqIBjcnhXAAKn06Z/GgDrY/jfZiJJL7Q7pFc43RTBx79QK9C8P8AinRPEEKyaTqVvMT/AMsywVx7FTXzBouh3evahZaTpaEzXRO7fwiD+J+Owq34z8EX/gzVUjlilvIZFDR3tvGwB9R8pypFAHffF2RpPFN/Jq39oWxsbZBpEcUZeK6dj8zNjjg9jXBah9ou7OBL0XKLakuSsBUBsZ749xU2k/EHxloNjNYC6bavzIl/D5kiA91Lc4+ua9c8Aw+IPE/hy21HxXeWc1hdwvuiMShmXsxYfd70AeQ6Zp+kX9te/wBrC/srhoS1pNH8y59XHYVjyrDpwt7iNw8qAbc/6tiOpH/169j0bR/DXi6wnsPCmqXMUtq5SSWWPJZQeg9R71Q1P4MajsYafrFrJznZNFtxn0PagDgHsJ9Yvnls8XkLGMXl1AmEhV8HnvxmtqK3s9RvZtGi0bU8WU3k21xEfk8v+J2J6Dvxmt7w34E8ZeEotYW0gsJY7+38p2SXK5Gfm2kdea55r2d7mDSr/V2sElAjmw2QvHJOOcfWgB9tpUkPxFstD0XUVEc8Jb7coAESYJIz0J61x+vBYtcuLOC4ma0tp2j8zgiT1fOeal1S3fT57WeK/hu7VpTGHgB2tzjnnioruwC6iILaQyQFyinI6nHUY6UAX/CxuYtfsBYJK9z5u9WMZyyAHOfQVd1PTDJrV9HbeI8zB/NmMYbYGfJ2jkdMfyqxBrmp2tvImlTRW93ZKYBcKAxcnqgz2rkNQ1XU5Cm2S2hxnJYBdx6dhz0/WgD7M759BzSFFbKOAY3BUj2NDnC5px5oA+ctVsLfS7+7ilsxc3un3DxmLJCun3gcd+DUuh2WnazdS3ssElpYIvmTQ53ROf7gHXdXXfEXRJZ/HsDWkUzvfWw4R9oDL/8AWNeZakl5ayvp1wZ4vJlLKoTOD6nNAF+81zw+ZvsFto8xtI3MkT3HEq/7P+77GqtxbaPextJGZLZl4ZHPIz6etU4r1vPd1VJpShiGB83Pcn1pFWzu/ImugqSWKBZAOs+OP++qALF1oE76OdRspEuII5PLdXGSnufWslI0SGNTGVTqyAYHvgd/rXUPdXHh7w/ahIy41ZGuFhJ5RO2feqcDwa3CYGUR6ii5TZ90r9aAMaG/mZlSa0RIoTmPax49KuXavfCHzrRI3YFw4BUsPeof7N+zs7AQuqEH903X6gVsi8tb7RrxLwyC5jVfsJhORuPBUr6UAU7uyZIPPEJ+zgAu8R3og9zT1s7200y5uZWWS1KeYnzbhn+6AKelneHwhfDTrp7Y28uLq0bCeaD/ABL9O4rU0HwjrTeCl1WO3hVZQyC3mJVpB2cH3oA561eWTTLTUfNf7VbSmRS7k8dV7+1e+x/Efw5GLKK/1JIb2aJHePaTtJ45PavEvDmno3h+S5Ty5rmO6WJrKZiHAJ5b6CodR0jWIr5biLTlDtN5MJBBDtxjFAH0ppOs6fq73I0y5S5W3YJIydAxGcVB4s1638NaJNqN0rSbSEjiXrI56CqngTw6vhzQ1hmIa+nPnXcueC57fQDivKPiR4kl1rxIEj89NKsSyRbRkSt/E/uOw+lAHIeMfEV3r+pPc615jyFMQwIdscI9h3NdFZXmh6BpcFzr1o95danbCWCzhX5Yo+zM3qaxdC0eDxH4q0zT2kkSzuSQSTgkDrt9wa9C8eeCtKbVLJ73UVs9NsNO2m3UfvbmOPkhffjmgCppmkaf4sttK1i3t5dF060Z/tbTthCmOCmeDms3TdAt73xMmlWGo6XdW5kaRGXJZ069M449q4PxFr93rkpw7waUoCW9mrYREHQEdz610vwQsvtPjeO5AbybGFpmdc/KOmPfNAG3q1jZ2M7SaLrK3lmN0crBMeW4PKf0rX8B2di+oLfWz3U8boz+VHJtEZUZIHfrT01vwzerqcrQm10q8Jk8oDEss4Yg8ds8GneE49IsdXuLHTba9hM9syxSTbjvJ6j2FAHpXh3VV1vR4L9YJLcyEq0Un3lIODmtGs3w9afYNItrfncqDKnsT1rSHA6596ACiiigAooooAKKKKACs3xFpOna3pM9lrMSPZuOSxwUPZgexrSrzb4131zpuiQvC0v2ad9sqoRgkfWgDV8C+ALPwlqF1eQX0175sYjh81QPKXqcY6k+tdqCR0NcT8Lr24udKMU00ssKxo8XmLyueozXakgKWYhVUZJJwAPU0AeZ/GLwdF4oNtNaXUFlrUCERPcMFjnQ9Vz6g1kW633w60q306/nJ8L2tu0uoT4DG8mkGBBF3GOTxiua+MPimHxNrMMGlFpdJ05SGu0+60rccewrmoprO70uPRNVlntbSa4EsMqsX8uTGM7PTmgDovD6abB4gjk+GmtSyTzjzhYTpgwDuvP3vpXufhfUb3UdMD6pDDDeqdrpESVPuM9K+bZ/AGvafrcdz4Xu4tY+ysJGubU7fKI5KkfTtXqlp43lsoItRmtmeFhslRVIYOOpA7CgCr8bfHOtaBMdI020EEc0Syi+DZbb3AHbnNeYa/FotxYaRceGLvy9emiJv4pxu3Njlgx9816Z8ZZrXxB4Y0PWNK8qa1lk2SOwGQp/hPpg5ryCfTnhkljSTiOPdIyHCx+gz60Aeg6d4Et4vh6NT1jXbVZuZUhgwEJ6iM+rEgdK4bT4p9T1lV1AJp3nsflX5fKwOD9T61nEWFtd6ekoIjDDejOSevLCuy1yfSiE160Im0mF/s6wSjmVgPmJPfHYUAchJHeRNLGIGeTLAMCDgZPzCs23j8yMCWSJgvAEhGV9a7XTLL/hIdSt4dFtkSO7k2o8mdkYPWquo6BbaL4h1LS/7TtLie2ZBK+3ABIztGeuKAPq48qfpS0CkXpj04oA4v4qPNp+kWmtWik3FhMOcZ2q3BP6CvHfFkpvdRN3cXHnXNwA+5ejYHHTpivorXNNi1jRrzTrgForiIoQDjnqP1FeCvb+H7O1W2ur6Z7hSY51WPmLaccH14oAo/Dvw5q974hsZ7O132sE3m3TXPAUfQ8mvRvG3w5t9Xnjv/C/2WC6DYnjUgLKCeT7Gs3xj43T/hGf7O8MQ3MDtb4a6YqrIAOOM5Oa848P67qWgaFA+nahJG08rNIzZOR6LnrmgDa8d6LP4dsUL3E00bO0MagZVcdQvoKqQaRZaVDHc6k7fYL2zd4JLQ75VnOMKwHQVXe6Nv4KmuRPO6vqIATcJDG3ORz61o2ek+HtR09JLLxBLaO6F1ivI9uJB1Udc0AZHhXS/tt5cm0jzNaWfm7k5bIPJPr1pJUtIbqxnsQyPdr84uVwFOeWT2qTRdVi0TxXby3UabHP2eY252go2BWj430260uY2twxnijkZrKUkZ8tucfTmgChpnhm/wBcuL+G2u57uFH3RzLnbJjqc+1em674us/AOnaZ4fmjnv7mCFZQzEYKjkDPtXIXNxrlt4IttPfFu8RJ+0IuEYE9CR7V3cuh+FPiFpVpqmqmRLrT4At1JExjO0LkhvVeMg0AZ2la7plp4etdX8QK8h1pyYtOgjH7lSeuep+tRfDTRrWzvJNWnknisI7hxawXb5IY/wAQ/CuM8aWV54h1OyutFht20Xb9ntIbV8mOGP8AicdVzU8cF1JYC+0+Saa0tsrDGsochu/GcmgDqvit8RiFudC8P/MzLsubwNgpn+FPf3rm73wfq8GhaNc2iy3EzoJJYA2WVT0wB1zXMWbnUY5FupHTbOHuN8O3Jz0P4CvTdWt/FupePtHsonuo/DTCN4prNfLVYtozlhnn60Acxf3Vx4c1PwzcX9m6y2khnIkG1thPIr0z4qava6fY6ayWsN1qMjl7USLnC7fmx9QSMe9cX42msWjmtLo3Fxq1jM0Ry+8rH1Qse+Rg1a8Za6niHTtIXTmt5b20jDzYPKFhjA9OtAHK3PgeLVdFvtf0W7j0+0jc+ZZ3uUw4HKqx4+ldJ+zmDHY+JZ3jGwCMF/oHytZuh6idRhk0jxIQmnSI6mKUFVMx4RwcdQa6TwyNQ8FfDvU7aO1028vYn3+Xbz79yMcFpPwxxQBlx6FbXCWNrZ6eXEk73Et0XAVHJyFHpwRWl4bsBrPiQ2E8xmisiJpJUPzKwPygH0PSmaHrbWVhFptlGkF3qM37mBQWVSff0xXpuh6RbaPZ+TbxRpM53TyIMeY/c0AX+d5PQUuMCiigBF3Zbftxu+Xbnp7+9LRRQAUUUUAFIARITklSOQT0+lLRQAibtg8zbv77M4/DNcf8UzYy6DaWOoxGRLu6VBg42YBJY+w4rsa4X4vm1i8MmebTpdRuvmhgiTPybsbnOPTAoA4Wy8UyaL4OsryyuXKNrAhEqrgyQjGV56jmj4q+Orq7S6sLC4hGl7E3+U3zuT/CT+PSoZtFj1HSdA8Lz3NtDNb2kl3lmAQuScE+pAxXDajaxm8t7GG6tpv3nkmZuEZs/ez7GgC3p+qaNp1vfx/ZLjUZ71Y2hRk2LBL3z645xVUtlTJbyO2os4+4pIIB+8Pb1q/c2N9a2BsbiW0YR3PmtLG2ZJeMZUdcc1K2sxaV9igW2gG8Fj5bYcj6Y4zQAy+8R6uLq1EUy6fdRuWj+zxlRLIB/EfpT77xXqWp24juo4mdT+92Lgk/1qjrHlSX8bQgywrGTmZstHnr+NZgdRJCII/NQdHPysRnkD6UATz6zcroEmmxxzNbmYMqAEKpzyc+tNupdQ1PTobRVR7eBvNlCR7nKAfeajUTe3NubG0ube3tFJm2FsLn6nkn2o8KXN9pkOoDTbzyXeAxFymVZWHIyeKAI9Pgtta1KVIJvsti4WMSOuWRugz9TUFwNTjkg0KcI0Nq7ShIjhTj+LPcmsnU47vTvIS0ebbMBIzFeGYdjXRyeXbWNvcamLizErKo8tOZFwckZ6UAek/C29tLWzh0rTLWJNZa4Ek0k7Z8uNuwPY8dBWTr3gnTfFfiHVL/AEjU0WZblobuEniORQBkE9c/0rE8L2T6hp2pyaPewW0FqpmWYk+YzA8KeOtZ2l/EN/C8928nhzzbi+ZZJnckB2AwWH1zQB9Y96QdfrQoIBzSmgBQcEGvm/4saKukeNrsp+7ivU+0RA9CTw2fyr6PJwpPpXlnxw0xZLbR9bMOfsk/lzsOoRun4Zz+dAHE+DbK3urCLUtXvvsdsA8EcrIWWd1HSuZ1i8fV9bkSclreIbbaIptVQx56dCBXXal4kmvbO30ydYbSCAmUp5Y2BT0Ax3z3rkrlXmlN3aiR8OEaMDnDccUAXv7cs/8AhX9x4ZvNNWK5WTzoL2M5+YHq3vjj8aztHij1DU7SC/EcMcEbFpXORHkY3fSmzWcnh7xQq6l5EqW0q5tnziVSeQAOpFanjDTfsHiV4dLhnVJ0V0hYfPtbooHcZoAzYrezkSMXT/aGVjGjAYR+flPrXcaxrfhvQLuziGm3eueJbe3VBGMmKJjzgjknGfSrejeA5NMstP1LxbrFpY+WTItoVDE9wCeP5UljHaeGNGbxJpV0bq71e9a3m1V4wVskJ5wp688ZoA3vF3iLTki0vQNbs3KajaLPOU+Uxsf4MVzviPxB4s0fTrD7FpUenaRtMUtx5QdJk6KW7jiud1VWvddikj1V9T1GGVvNuGjwqL/Dx71PrWta69jqWj6neu1pK27YuGGBzwew9qAMXSdQttOmS70aWS2nYMbtFJ2yKf4R7H2qxbWfm3pOnO9lOyG4jRHweOv41jSTQWs5hhdmUoAoZOCfrXR+H7++tZrS2s1in1CWYGBZYw2cdRn0oAhOu3+ryxpqiiWF18uR/KCHGepPevTPhpqmuW+tzaHfI76Ulr9ogkUZEKDgIG7g1zWqeE9TWyu9YvJbKaGQu8kNvJmOIj+HI6ck1zOmarfafpwuLLVpIZosAxq2RsJ6c9RQB1njjUL298VyS2a281mgCvGQEduMZJ71xC5ttX1OFVEfzbjH93n03Voah593E2sLFBKZcxXCrL+8X0dR79arWtvd+Ib65tdNV5dTWH5ElwPN29efWgCS+huxBG0iSSWjLuj3n7pHqe4FaegQ3Mt3GbSRfMkwZ7aNuZkPGBnr61a1DStXubEprN5aWlvDD5cduZhuWTuCAM9qzrO2TSbJ7kOXvxGV35w8THgbfY0Aej/DvSDca9e6jdrujsiIbYEDardyPcZAr0isTwVpY0fwvp9oTmXyxJKxOSztySfzrboAKKKKACiiigAFFIwypGSM9xQ3qO/FAC0opufz6Vg6z4p0nTLs2l1dlJ9vLKMrGT0BPr7UAbX2iIsAjhyW2fJ82G9K85+JdxNY+JbHUbvWUi0yziwmnQHdPPM5wAV/ukY/KqI8UalZ6jPbq9ppdmYmuAjqTNKo7rzjJ61xnw/8XQ/8Jqk+t6etxPcvshuJxiQEngsW44AoA6OTwlca74ivFZxZmys0SKYL/Gw3MNucnBOK4jW/B1/okP2+FLbVYLR1a5dTtMQP95c8D3r0bUNM18fGuw+zPKNPbE7sD8mwfeB9Sa5XSNattZ8WfELRY4RayaxHIkG5jzIgIwc9CcfrQBx15dbJry9zFEl1/qjH82B12AnpVPw1BYvqoTUd8kEkbOi5IYt2yT2qtNItxAtu00rS7grlowAjgYKgCuiht7r7CzXEcUk8aIkLBfuHPRqAMbULiKW8MDsYZYgVQ47+/PpWl4X024Ph7V9XWOGS1sIvnabOASeOnequnaJe6xrAt7mGWQmT99hOABglc4rZ1/Xbi38P3ujQww2+n3c/zRoMMqJx788UAczYIk7Dz5fMwyqwIxkH+76fWrWppZ2sqfY5QRISqRZOFj6EkdzVK1lw9u+Xjh379zAZAHXP1rR1TXAsLPHbRN9scqSUGY4x3U+9AGNfXXkyT2qPIQjbwH6Z9FB5qbQbloL4Jq8i3Ejr+6aXLpGe3AqnrcLXM0EkcjSREBRkZZT9ataNpZOtW5kdYICCZZAcgL689/agB1trmr2c8N1aSRSFJWMkKKFEgB7r6V6PeyxXi2/2jTXmi8sSxBQP3e8ZZc/7wNcR4ctdJudU8i6vTHYB5FlvFTlfTH1rufC/xCsvDlnJY2Wjie1RysdxcPlpcd+e3NAH0CM9+vtSijrg0DvmgBrDKMvcdKoa5pcGvaJeabdZEV1GULDqp7EfStE1Hko3YqT+VAHzvPoEqibSr4yWYtX8prhk3GQ54Y/7JrsdU8JaXpXgptTubkxyBFFxcWrfKQD1UetdP8TFltdKXVLSzFz5Z2XKj/nme5+lcJ4c1Cwv9OktNfvWgd3ZE2R5hCt0yp4/GgDzw6k9prMctnD9rSGTehuxvkJ6g4q1rWsX+tauNTkZluVtx86g5UA8kemK6XUPB2q6Zqdja30NvcxyqxW5Q7GIHQkV0fhO0sNKSK/TbNDas0V9Ifm3hgRjb6CgDy65ubm7s4bnUJp7mJeEklfc2O557ciut0XW1vfD2meD721he0efzpJN+weUDuxnseetVPHa6Pc6ib3w5sa1cbJLYKQoOeGVRWdoUN4mpQRmwTyH4kE2Nr/7Jz0oA0PF8N5Bqq6ebSGxtJzutpkc/PGT8oZu/Fc/PFNaPtt7iBHiQwuplzvx35re17V5dc1i5FzKBFEB9lhC8Q7eMLjqOKxtOWUQyyNaW80C8PKxw6E9selAFHXrOe1u44HkiuonjWRTEdxjB7HHeuz8CTSLLK8cAnvoLN2tInAxvxjPTOcE1i2+lDTbQXi39s9jexsUS3IMqtjoc81oeBrK68Ranp8D77KJJQ7XK/KzIvYfU0Adz8MfDs+mfDbW/wDhJ4JrZb8ySvC5OVUjrjsSc/pXj8cQ/sxRNg7f3alD88nPH6V7R8RPG9nMLnw7ptpJqMUqGG7mjk2+V04B7muNktPD8nhmxutJJh1axkEBt5QN86t3P4UAZfgnSjca2YJLg29lIgRJfLDEtjjPHSn6VMNI8QRzWU3m3FpOGDgdVB+bn0IyMV3GgQ6X4atp7m8vZbG4DBgQoJYr2VT1B71la54fsr3U/wC0NJ1iyEN7GSERhkSseQV7UAYXjGXTNV8WXGqaYVQ3Kq0kJOD5g68+9b3hmEavqdjp8unLIZJlmuLkA5AXoCfQYrB/s/ybq/tLvTbkS2qgyKThWH99T+Vd98GLCQnUtWJcW8mLeFSfvAck/wAqAPTzjPHA7UlFFABRRRQBHceaYX+zbPO/hL/dHPf8M1IM4AJyR1OOvvRRQAUjZ7GlooA5D4n65d6D4bWXTWWG7uZ1gWY8iPPJNeDX0sghgkmP7qaUtwS5LZ5Y+5r6C+I+htr/AISurWIE3ER86IKM7ivOK8b+HF5pceo6jLrdwI4reMva28if8tB1A/woAypdcmntZLS3hC3BkG69nUl0RefLGemcV03iHRbrxho9t4juvs2n6faRYwpAaVlx0x681i6TZyeNdY1TVbu5W1mgjJS3jTYJRyFCj1qs+sPpvge80o2dxY3U0oVpbmNihAJ6Buh+lAG34r8Z6ndy+G5dORrIW658xJCRuHRXPcY7V0lprun694bvfFMPhLzde03fGJo0AVpMcycfeA6nOSK880U6lq2jXelmIeZg3MG04WQDqMj+VN8B+L9dg03VNDsmjjtZ1kkkmkX5rYY+YigDC0y21C6cWkdvJdT37FrZo1G15T1/KvVbHxLonhXwNpVtq1vcPBfb47m6SISG3mUjIbjnHavO9GvRK6w6ZftbQ6chuYXnXDNg/MoPXnmvX/h1pOjXug31rZ3cN40p817S7QOiu38W08/jQBzXjXxbc2IutP0KzthBNCksWoM3MiMuCQvrXk0Qe0t54L+dA7/6tcZYk9yeor074gWGqDU3udX0NLSG1iEVtPajMOc8YPasbTfhhq3iaNL2SQQwocM7DdLN3yKAOW1YG0s9NgS3aS4IyWIzznkHHHvWDLBN9s3Ry4lQ52Hpz2HavTvG1vBY2umQiSNLq3drd7eP5iMfKHdvXjpXmNwhtZndm2eW2eBn5vQGgDp9Plt9M8MahcCNHubl1t41kORGn8RUnvSNaRro8uqxshtoWVGt5nxLOx7qPSq2n2C3tnYXGtanHZQMGMaSZLls9QvTHvVhIY9QnaC0eK5S3O6S4K7UA9v/AK1AFeWKSeRWZTAQ2+K2iTAbI/ixWfr1xLprQRq+SwJKSRAlOf8A9dXbzVH07UpEtYnubeUKkbg8s/8Asj68Yr3f4a/DuC10Zr7xHbh9VvtsksZ5ESjO1frg5PuaAPR7u7itbczyCZ4wQuIIXmbJOPuoCfxxxUgMpl4EfkkAgnO78ulGMHcnBpW3EcHFAAWx3GaUcjBpjgfh3FNU8cfrQA50Xa6OqtE42sp7g14x4n0O18IeIYGaOS40ydvOjQrwuOSg7cCvagcjkfhVPUtPt9QthBdxLJGrh4yf4GHQ0AeS/Ea2l2+HL+3vHlsrmRlheSTlAwyF57Vx+qx2+n6nILyQ3NvGMBQ+DuYdM+1fQWuaHaa3pC6fqEYaEYOIxjaR0K+leWyeG7S11a80AJl7mUNAJ2y8xHUhugOM8UAcVba1YJ4cMEcKrrkM6S2lxJxG3P3T27frWj44tZ9e8RaPcQWpXUr/AGJPaqeFcAfMCOx9a2vFXh+PSZHubK1h1fRocQvHbYLW0n8W7B+ldh4Hnmi1oRnRra1WTTxNbSb90hAyMH0oA8n8T2UGj3E2iXFuo1SIiRrmJySqn+EDv9ay7HTba61JWubwx22GTzC/zb8ZH4Z4rsrtdW1q8vrfxDDAt5Jl4pIgAy+30xxUOleGnsrXS4L+wgn0vU7s8E7ZEI/umgDkbOS8snhiEaqvm7WSVCVBPG4Gun023fXZRb218dPuo5sJDbksojXln3Vnaxo50zxBfNp89y1vayFCkh/1a9gT/KnQSvp1y2r6WR5ykSBs4yvcenagCjrs1pLeXE9hHcyxFzmaU480gYOCKqaBfBL2G4WCTyocSyIp3cA1J4j1SXV5xfTBbTKklYRhCD7VV8LRK2qPtYNbvCyy4IGQfrQB6V4q0iO/+H0mtQX7yulyWiZ48Ehn4X8M1w2lRNc3aW+oQuhuD5asDsyR1atW9uNU0nRbbS4rsvpx2u8QQsqnPHPr7VDO1xFDGJXcxp92Tvz1/TNAHfX3iGG90eOIraX1/wD8eSonDIemfcc/pXpGg6VBouj2mn2qBY4VG4epPJP515X8HfDEc102syCQ2kDfuBLz5jnPzD6f1r2QZJJOMmgAooooAKKKKACiiigAooJxRQAA85HFeNfFfwdNprXHiDSCz2ZbzLq1UY8o/wB9favYz7cCkkVJYnjlVXjdSrKwyGB4INAHzr4YfRofC2q6pdXNwt5alZUgiORknAI9euaqeNNWu/Ep0+LUYNxjh8wXHXzV7Ajpmuy8e/DaPTVlvvDyn7FIT59qct5ef4lx1XpxXmkt2yRxxW7CUQNjcVOQ3fjHFAEmlwf2VpbarYagrajHJ5dvZbAOOpJ9ua7fxfpX9v8AhKHXfB9uoZyE1Sxto8O79z69e3pXK2sUupaSbiPaGEwDylOEyBXY+DNUuodQs7LSNkdoA63UgAAkAByx9MdaAPIrt1hvDBLHIbkfIY9m0q2PuEV6d8PdG1uTV7C8i86zj2GHztuBHxyTnr6Vz9l4Tk/tY+IrC9W70izvg81yh3uF3ZJKivTNV1251Pxtb6JpjummX5+YMBtYAZLLjkUAcx4n8ReJrS+utBvNQtdbsmPDLD87g9gw7is2Lxzqvhu6srKaWCPTSuZY4/8AWjJ6k9sVh61ps3h74kLYDUP3cVxuMzN8u1uSMeo7/WtDxxZ2V3BqmraUbGPThOqERyZnb5QGO08gE0AbGpafqT6gi6vYDWNN1Ab7LULVQ0kY9ZAO3vXD+F/CkGoa1HaxagJLSSfZKzJh054Iz+VT/D3xVrek6klrpsx1C2uo/si2MwJYr22+nWq5vLzwVf8A2dvLs9Rcbmh2Z8lT2PqaALfxL0250rxc9vCUuI7ONY45XyN2fT3FUtUhvdK8Lu91MiTXcoLiIgskYHfHQ5I610mq+INK/sTw9r91BPe6us5Z4peFlC9Fx3rsPh/4Bn1nWm8TeIo3hs5nM9vpzjoT03D0HYUAZ/wZ+GhnFj4k8Sq5MZ8yytH7jtI49fQV7oxZicEj39acMdFAGOMDtUck2w4Vc+tACo6sMg5xQ5IAYc+wqujkDpz7VOrqSRnBNADGbODjn3pM5PbNOdCPu5x/KmHBXk9eD7UAOU7Txmpeq57H0qAeg6etOVtp6ZoAW6hM9rNB5jx+YjIJEOGTIxke461xh0i6l0a50fxHeRJI7GO0vgdrydw27+FuCMV3AORkVDdW0F3B5V1Es0ed21hnB9RQB5VYy23gq9t4dIga8Djy71EfcJm/vEnjdW7rkz6Rpd7rpjaC+niFra20j/KgJJx0461rxeF9P0u/udStLSW6eRcGDfx9QPWsbx3eRamIdLuZ4bO2aMTCSdTvWUdFX1oA8f1FxP4tEs1zcDMQjjVSckkYCDHau/8AHl5Ho2keF9HunuY7q0i+0vNFGZPL4xk9PWl0fU9M0S5s5Wsn1G4I2pM6hQG7kZGat/Em6t/tFpqSGV4bqLZIisFwOmTkdKAHxGwuPDL3V1cJrVzODP51soSR06LuU9SM81iaD4Ui1uzjTVbuSC2uSWtnjTAQDs3p1PBrmZoYonhjsrO6g2qWxGxZmHbDDtWrZ+JdbtdFkgs0C2iOVlWRMqGI7mgBlvplhpU2tjVNUs1W0Xy7WTb5okB7YFc3YqiQXlvEY2ZmAAEZJYk8BRXSeItF06/0fStQe6s1upFPnRQZDE59OlXdCt7C5udPg8i6t7uNxm4YjLY6KABQBNoXhiKGKDU/E18LW1WUMluWySfVvTmp9I0NfF/iOX7NC8WjwvmafPEnoq/54rvpfBWmTX73F0ryJIQ8kTsTvb39q6SCKKCFYbaKOKJfuoi7VH5UANtLWGytIba0iEdvENqIo6CrA4pvG4kjpxTuooAKKKKACiiigAooooAKTHB9KWigBO3GKQqTnGOlOpjoGKswyVOV5IxQA4Hgc89K43xV8O9I1+4F1GX0++By0tuAFk9mXvXYFTnPGaFbsSCelAHk0nhLX9LZYhbRXVorHaYCArDtuX1rh/EWptFrMdhbokcq5M1ujBCSeqN7GvpPcM4zisXU/DGg6jdi6v8AS7aa5znztuGJ9yMUAeS21k1qzar4YspdFspUFvexI3mQ7+nK/XvVey03UtI8faBbM7x6huMyO5zE6/xDd2yK9eHhixtdPvrXTTJareNukIcsAfYHpXOWPgO4trhhNrUtxZg74w4zID3G49qAPIvHzvP4u1KefTHVppDJlvuKBgcN+ApdU8HSaK2kazdyLMmosFe1V/nZT/FgdhXseq+BBrBEWo6rO1mG3CGONVYe27nNdBp/h3SrNbby7ONpLZNkUkxLsq/jQB4wPDqeGtfik8JWmqXd3dQAi5SPCwbuSAT3wetdZ4i8Lax4surO+bQtNsJ0UK0162+VcdyBwfzr1QP5YwDgdgo4pk4Z/lVST656UAcV4U+G+laNMl5fO2p6gvPmzKPLU/7Cdq7rO7PX60AYUAdBxTZH2D1Y9BQA2QiNdqfeNVyTnGB9T3p4BcHjJPJp3lsOpxQBAmCPTFO3cgMfwqRoVMKSLxuXOPSocndjNAEyuRjBBHvSl0bO5ce9RLycGjBPQ4AHpQBL5eRlSDSMpBwc/XNNQAjPfGeKXeye/wBaAFRtvIJPb61MrhunOaagDjoB9KQjY3BoAkxjO04rP1nRbDWoFi1K2jm2HdG+MMh9QeorRooA4LVvAc013FNa36vbxA4t517/AO8MVz1vZakdVS08QaVcS2DHAhVRKiHPUMe1evUZoA43WtBu7m0FpoQGmeRt8mYRjDr3U1yUvhXxDpJliigmvUu23ybG3rn3HavX6KAPG9M+GOrPcG5mktNO3clWJlI55IGcA9K9D8N+FdO0AF7cTXV2eWuZzvbPfb6fhXQ0jnA4oAT5vTn607v1oAxwST9aKAAcdKKKKACig0Z60AFFFFABRR160UAFFFFABRRRQAUUUUAH4UmByMClooAQjPem7MHrkelPooAaUBNJjORt49afj1ooAYqYOd3HbAp/0oPFB4FACFsHAGTTCqrlpDljTWc7toGBjtTGUHkjJBoAe0vXaMD1qJtx7E0E88cUjZJ+8aAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Central bronchiectasis in a patient with allergic bronchopulmonary aspergillosis. Multiple dilated third and fourth generation bronchi are seen. Smaller peripheral bronchi filled with mucus account for the branching linear opacities in the distal lung parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3682=[""].join("\n");
var outline_f3_38_3682=null;
var title_f3_38_3683="Incidental detection of DDH";
var content_f3_38_3683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Developmental dysplasia of the hip detected incidentally",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 590px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Routine cystogram in this 2 2/12-year-old girl revealed disruption of Shenton line (dashed lines) and acetabular dysplasia (arrow) of the right hip. Note normal Shenton line on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3683=[""].join("\n");
var outline_f3_38_3683=null;
var title_f3_38_3684="Muscular dystrophy inheritance pattern PI";
var content_f3_38_3684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Muscular dystrophy inheritance pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duchenne, Becker, and some forms of Emery-Dreifuss muscular dystrophy are carried by the female parent. These muscular dystrophies affect 50 percent of male infants of mothers who carry the genetic defect; this is called X-linked recessive&nbsp;inheritance. Females who inherit their mother's defective X chromosome generally have less severe disease than males.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3684=[""].join("\n");
var outline_f3_38_3684=null;
var title_f3_38_3685="Denosumab: Patient drug information";
var content_f3_38_3685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Denosumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     see \"Denosumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10267890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prolia&trade;;",
"     </li>",
"     <li>",
"      Xgeva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10890558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Prolia&reg;;",
"     </li>",
"     <li>",
"      Xgeva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10325284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10302715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3448744",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop bone loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used when treating some cancers.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10302688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2789825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to denosumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with a sex partner who plans on getting pregnant at any time while you are being treated.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10302690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have malabsorption syndrome or have had part of your bowel taken out, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had thyroid or parathyroid surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a dental exam before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10302718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698211",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698212",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the jaw bone may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10302692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4044623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any new or strange groin, hip, or thigh pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10302717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10302693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15576 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-287B6DBA01-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3685=[""].join("\n");
var outline_f3_38_3685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10267890\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10890558\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10325284\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10302715\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10302688\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10302690\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10302718\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10302692\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10302717\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10302693\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=related_link\">",
"      Denosumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_38_3686="Supracristal VSD subcostal 2D and color still frame";
var content_f3_38_3686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Supracristal VSD subcostal 2D and color still frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paired subcostal parasagittal images of a supracristal VSD (arrow) located just beneath the pulmonary valve.",
"    <div class=\"footnotes\">",
"     PA: pulmonary artery; RV: right ventricle; IVS: trabecular portion of the intraventricular septum; LVOT: left ventricular outflow tract; LA: left atrium; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3686=[""].join("\n");
var outline_f3_38_3686=null;
var title_f3_38_3687="Exercise assessment and measurement of exercise capacity in patients with coronary heart disease";
var content_f3_38_3687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise assessment and measurement of exercise capacity in patients with coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3687/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3687/contributors\">",
"     Lynne T Braun, PhD, RN, CNP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3687/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3687/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3687/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3687/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3687/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/38/3687/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have shown an inverse association between physical activity and coronary heart disease (CHD) incidence and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Fitness also appears to be important, as a graded relation has been noted between the degree of fitness and the reduction in coronary risk (",
"    <a class=\"graphic graphic_figure graphicRef60770 \" href=\"UTD.htm?8/13/8414\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Among men with and without cardiovascular disease who were referred for treadmill exercise testing, peak exercise capacity measured in metabolic equivalents (METS) was the strongest predictor of the risk of death, during an average of 6.2 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/6\">",
"     6",
"    </a>",
"    ]. For each 1-MET increase in exercise capacity, there was a 12 percent improvement in survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=see_link&amp;anchor=H3#H3\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\", section on 'Exercise training'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise is also a key component of cardiac rehabilitation following myocardial infarction (MI). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=see_link\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of aerobic exercise are mediated through hemodynamic and metabolic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/7\">",
"     7",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aerobic exercise increases physical work capacity, lowers resting and submaximal exercise heart rate, facilitates the loss of excess weight, and reduces blood pressure. Aerobic exercise also increases the dilating capacity of coronary arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/8\">",
"       8",
"      </a>",
"      ], and may promote regression or minimize progression of coronary lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/2998?source=see_link\">",
"       \"Exercise in the treatment and prevention of hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"       \"Endothelial dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aerobic exercise improves glycemic control and induces favorable lipoprotein changes (with a reduction in plasma triglycerides and an elevation in HDL-cholesterol being the most consistent changes) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"       \"Effects of exercise in diabetes mellitus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic moderate exercise also improves muscle function. These changes include increases in the quantity of mitochondrial enzymes and in the number of \"slow-twitch\" muscle fibers, and the development of new muscle capillaries [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/12\">",
"       12",
"      </a>",
"      ]. In addition, the action of insulin is improved with exercise training by an increase in the number of glucose transporters that facilitate diffusion of glucose into muscle cells [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Aerobic exercise also improves the peripheral muscle utilization and extraction of oxygen during exercise in old as well as young patients [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of anginal symptoms is also reduced by an exercise program. As a result, aerobic exercise is beneficial for",
"    <strong>",
"     both",
"    </strong>",
"    primary and secondary prevention of CHD. An exercise training prescription and program for a patient with known coronary disease should be designed according to the individual's health status and current level of physical activity. Prior to the design of such a specific program, it is essential to perform exercise testing for assessment of risk, prognosis, and functional capacity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the testing procedures and requirement for monitoring when exercise assessment is performed and an exercise program is initiated in patients with known CHD, often as part of a cardiac rehabilitation program. Depending upon the patient, one of two goals is appropriate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of functional aerobic capacity and prognosis in patients with known CHD to serve as the basis for an exercise prescription.",
"     </li>",
"     <li>",
"      Evaluation of functional aerobic capacity to help determine an exercise prescription for patients with CHD soon after an uncomplicated MI (usually within three weeks) or following coronary artery revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of exercise testing in the diagnosis and post-MI estimation of prognosis of CHD and in stratifying patients with congestive heart failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maximal exercise testing is absolutely contraindicated in the presence of active cardiovascular dysfunction such as an acute myocardial infarction, unstable angina, or serious arrhythmias (",
"    <a class=\"graphic graphic_table graphicRef75978 \" href=\"UTD.htm?18/48/19211\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/18\">",
"     18",
"    </a>",
"    ]. Relative contraindications that can be overridden in certain circumstances with appropriate precautions include significant hypertension and moderate valvular disease (",
"    <a class=\"graphic graphic_table graphicRef56030 \" href=\"UTD.htm?38/17/39195\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Emergency departments are increasingly performing exercise tests on patients who present with chest pain and are determined to be low-risk for a cardiac event (patients who are no longer symptomatic, have unremarkable ECGs, and have normal cardiac enzymes). Studies have shown that the use of early exercise testing in emergency department chest pain centers is safe in carefully screened patients and allows for efficient management decisions. However, exercise testing in this setting should be performed within a carefully designed management protocol and only after patients have been screened for high-risk characteristics or other indicators for hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing is considered a relatively safe procedure. The overall risk associated with exercise testing in a mixed-subject population is approximately six cardiac events per 10,000 tests [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TESTING PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;During a maximal exercise test, work rate increases on an ergometric device (ie, speed and grade on a treadmill or resistance on a bicycle ergometer) until the individual reaches his physiologic limit (VO2max) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/20\">",
"     20",
"    </a>",
"    ], which is determined by the maximal cardiac output and peripheral extraction of oxygen. Maximal exercise testing allows the individual to reach his physiologic limit. This is observed when the VO2 does not rise despite a further increase in work rate or an individual reaches or exceeds his age-predicted maximal heart rate (ie, 220 minus age in years).",
"   </p>",
"   <p>",
"    Maximal testing is the most accurate measure of functional capacity, although it requires a highly motivated patient and carries some degree of risk. Submaximal exercise testing implies that the test is terminated at a predetermined point. Examples include a predischarge post-myocardial infarction (MI) exercise test to 70 percent age-predicted maximal heart rate or a symptom-limited exercise test prior to the initiation of cardiac rehabilitation.",
"   </p>",
"   <p>",
"    Various protocols are available for both maximal and submaximal exercise testing (treadmill, bicycle ergometer, step tests, distance runs, walking tests). The decision to select a given protocol is based upon body size, level of physical fitness, functional ability, and available equipment. In order for measurements of time or rate-pressure response to be directly related to the actual cardiac work, the subject must approach a steady-state. This implies that continued exercise at the same intensity would be associated with the same heart and cardiac output. This usually requires two to three minutes of exercise at each stage.",
"   </p>",
"   <p>",
"    A number of variables are measured during testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Maximal heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maximal heart rate can be estimated by the following equation:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Maximal heart rate = 220 - age (in years)",
"   </p>",
"   <p>",
"    It must be recognized that the standard deviation for this equation is 10 to 15",
"    <span class=\"nowrap\">",
"     beats/minute.",
"    </span>",
"    Given that this calculation was derived by studies in men, another study determined that the above formula overestimates the maximum heart rate in women [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/21\">",
"     21",
"    </a>",
"    ]. Therefore, it is most accurate to directly measure the maximal heart rate at highest exercise intensity on the maximal exercise test, particularly in cardiac patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link&amp;anchor=H25#H25\">",
"     \"Performance of exercise ECG testing\", section on 'Test endpoints'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Peak exercise capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peak exercise capacity is defined as \"the maximum ability of the cardiovascular system to deliver oxygen to exercising skeletal muscle and of the exercising muscle to extract oxygen from the blood\" [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/22\">",
"     22",
"    </a>",
"    ]. As a result, exercise tolerance is determined by three factors: pulmonary gas exchange; cardiac performance; and skeletal muscle metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise capacity can be quantitated clinically by measurement of oxygen uptake (VO2), carbon dioxide production (VCO2), and minute ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/23\">",
"     23",
"    </a>",
"    ]. These parameters are measured during exercise with rapidly responding gas analyzers capable of breath-by-breath determination of O2 and CO2 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The maximal oxygen uptake (VO2max) eventually reaches a plateau despite increasing workload (",
"    <a class=\"graphic graphic_figure graphicRef62094 \" href=\"UTD.htm?29/41/30366\">",
"     figure 2",
"    </a>",
"    ). Not surprisingly, VO2max has a strong linear correlation with heart rate, cardiac output, and skeletal muscle blood flow (",
"    <a class=\"graphic graphic_figure graphicRef63482 graphicRef65079 \" href=\"UTD.htm?39/27/40382\">",
"     figure 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is convenient to express oxygen uptake in multiples of resting requirement. The",
"    <strong>",
"     metabolic equivalent",
"    </strong>",
"    (MET) is a unit of resting oxygen uptake. Rather than using each patient's own value, one MET is designated as the average value (3.5 mL O2",
"    <span class=\"nowrap\">",
"     uptake/kg",
"    </span>",
"    per min). Maximum values occur between age 15 and 30 and then progressively decrease with age; however, they can be increased with aerobic exercise training. Values of approximately 12 METs are seen with maximal exercise in moderately active young men, while distance runners can have values as high as 18 to 24 METs. A mean exercise capacity of 10 METs has been observed in nonathletic, healthy, middle-aged men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anaerobic threshold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anaerobic threshold (AT) is another index used to estimate exercise capacity. It is defined as the point at which minute ventilation increases disproportionately relative to VO2, a response that is generally seen at 60 to 70 percent of VO2 max (",
"    <a class=\"graphic graphic_figure graphicRef62094 \" href=\"UTD.htm?29/41/30366\">",
"     figure 2",
"    </a>",
"    ). The AT is a reflection of the increase in lactic acid production by working muscles. It can be used to distinguish between noncardiac (pulmonary or musculoskeletal) and cardiac causes of exercise limitation, since patients who fatigue prior to reaching AT are likely to have a noncardiac problem [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/23\">",
"     23",
"    </a>",
"    ]. If the AT occurs at less than 40 percent of predicted VO2max, it is taken as evidence of cardiovascular impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systolic BP increases linearly with work rate to approximately 200 mmHg in normotensives and higher in hypertensives. The diastolic BP does not change with work rate in normotensives but does increase in hypertensives. A fall in systolic BP with rising work rate may be due to aortic valve obstruction, impaired left ventricular function, or global myocardial ischemia. The blood pressure should be allowed to decrease gradually following exercise. A cool-down period of a low-exercise workload is necessary to prevent postexercise hypotension due to excessive venous pooling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rating of perceived exertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rating of perceived exertion (RPE or Borg scale) is a subjective measure of exercise intensity and is a good indicator of relative fatigue (",
"    <a class=\"graphic graphic_table graphicRef70470 \" href=\"UTD.htm?20/13/20699\">",
"     table 3",
"    </a>",
"    ). It can be used in conjunction with the heart rate to determine the consistency of effort from one study to the next in a given patient. The RPE can also be used by the unsupervised patient to control the intensity of exercise. An alternative in elderly patients is the \"talk test\"; patients are instructed to exercise only to an intensity that permits them to continue talking to an exercising companion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17705?source=see_link\">",
"     \"Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other measurements obtained during exercise testing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The double product (heart rate x systolic BP), which parallels myocardial oxygen demand",
"     </li>",
"     <li>",
"      12-lead ECG (during and after exercise) to detect dysrhythmias and ischemic changes (eg, ST segment shifts, perhaps alterations in conduction)",
"     </li>",
"     <li>",
"      The respiratory exchange ratio",
"      <span class=\"nowrap\">",
"       (VCO2/VO2)",
"      </span>",
"      which rises above 1 beyond the ventilatory threshold",
"     </li>",
"     <li>",
"      The O2 pulse",
"      <span class=\"nowrap\">",
"       (VO2/HR),",
"      </span>",
"      which is related to stroke volume",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       VE/MVV",
"      </span>",
"      (minute ventilation divided by maximum voluntary ventilation), which is a measure of breathing reserve",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR DISCONTINUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are both absolute and relative indications for discontinuation of an exercise test other than the desired endpoint of attainment of the maximal heart rate (",
"    <a class=\"graphic graphic_table graphicRef79525 \" href=\"UTD.htm?18/56/19340\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/18\">",
"     18",
"    </a>",
"    ]. Absolute indications include the patient's request and acute cardiac events such as suspicion of a myocardial infarction, moderate to severe angina, hypotension, signs of poor perfusion, severe shortness of breath, and serious arrhythmias. Relative indications include electrocardiographic changes, increasing chest pain, severe fatigue, dyspnea, significant hypertension and less serious arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MONITORING DURING EXERCISE REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing as a measure of functional capacity is useful in clinical decisions regarding the appropriateness for exercise training and the type and intensity of exercise to be prescribed. The following risk stratification developed by the American Heart Association is useful in determining the degree of medical monitoring or supervision required during exercise training [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3687/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class A individuals are apparently healthy and have no clinical evidence of increased cardiovascular risk of exercise. These patients can exercise without medical supervision.",
"     </li>",
"     <li>",
"      Class B individuals have established coronary heart disease (CHD) that is clinically stable. These patients are at low risk of cardiovascular complications of vigorous exercise. They require supervision during prescription sessions (6 to 12 medical sessions) and can exercise without supervision once they understand how to monitor activity.",
"     </li>",
"     <li>",
"      Class C individuals are at moderate or high risk of cardiac complications during exercise by virtue of a history of multiple myocardial infarctions or cardiac arrest, NYHA class III or IV (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 5",
"      </a>",
"      ), exercise capacity of less than six metabolic equivalents (METs),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant ischemia on the exercise test. These patients require supervised exercise with continuous ECG monitoring until the safety of the exercise program has been established.",
"     </li>",
"     <li>",
"      Class D patients are those with unstable disease who require restriction of activity and for whom exercise is contraindicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Outpatient cardiac rehabilitation is typically appropriate for patients who belong to class B or C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25194153\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiologic studies have shown an inverse association between physical activity and coronary heart disease (CHD) incidence and mortality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aerobic exercise increases physical work capacity, lowers heart rate at rest and following exercise, facilitates weight loss, reduces blood pressure, improves glycemic control, and induces favorable changes in lipids. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic moderate exercise improves muscle function and reduces the frequency of anginal symptoms. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two main goals of the assessment of exercise capacity: (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      To assess functional aerobic capacity and prognosis in patients with known CHD to serve as the basis for an exercise prescription.",
"     </li>",
"     <li>",
"      To assess functional aerobic capacity and help determine an exercise prescription for patients with CHD following an uncomplicated MI or coronary artery revascularization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While exercise testing is generally safe, there are absolute (",
"      <a class=\"graphic graphic_table graphicRef75978 \" href=\"UTD.htm?18/48/19211\">",
"       table 1",
"      </a>",
"      ) and relative (",
"      <a class=\"graphic graphic_table graphicRef56030 \" href=\"UTD.htm?38/17/39195\">",
"       table 2",
"      </a>",
"      ) contraindications to exercise testing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risks'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise testing is useful in determining the type and intensity of exercise that is appropriate for individual patients. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Monitoring during exercise regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Blair SN. Physical activity, fitness, and coronary heart disease. In: Physical Activity, Fitness, and Health, Bouchard C, Shephard RJ, Stephens T (Eds), Human Kinetics Publishers, Champaign 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/2\">",
"      Paffenbarger RS Jr, Hyde RT, Wing AL, et al. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/3\">",
"      Wannamethee SG, Shaper AG, Alberti KG. Physical activity, metabolic factors, and the incidence of coronary heart disease and type 2 diabetes. Arch Intern Med 2000; 160:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/4\">",
"      Sandvik L, Erikssen J, Thaulow E, et al. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993; 328:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/5\">",
"      Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation 2003; 108:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/6\">",
"      Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/7\">",
"      Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/8\">",
"      Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 342:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/9\">",
"      Niebauer J, Hambrecht R, Velich T, et al. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation 1997; 96:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/10\">",
"      Hambrecht R, Walther C, M&ouml;bius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004; 109:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/11\">",
"      Couillard C, Despr&eacute;s JP, Lamarche B, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001; 21:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/12\">",
"      Henriksson J. Effects of physical training on the metabolism of skeletal muscle. Diabetes Care 1992; 15:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/13\">",
"      Seki Y, Berggren JR, Houmard JA, Charron MJ. Glucose transporter expression in skeletal muscle of endurance-trained individuals. Med Sci Sports Exerc 2006; 38:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/14\">",
"      Borghouts LB, Keizer HA. Exercise and insulin sensitivity: a review. Int J Sports Med 2000; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/15\">",
"      Ogawa T, Spina RJ, Martin WH 3rd, et al. Effects of aging, sex, and physical training on cardiovascular responses to exercise. Circulation 1992; 86:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/16\">",
"      Ades PA, Waldmann ML, Meyer WL, et al. Skeletal muscle and cardiovascular adaptations to exercise conditioning in older coronary patients. Circulation 1996; 94:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/17\">",
"      Arena R, Myers J, Williams MA, et al. Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. Circulation 2007; 116:329.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription, Eighth edition, Wolters Kluwer/Lippincott Williams Wilkins, Philadelphia 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/19\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/20\">",
"      Balady GJ, Arena R, Sietsema K, et al. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 2010; 122:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/21\">",
"      Gulati M, Shaw LJ, Thisted RA, et al. Heart rate response to exercise stress testing in asymptomatic women: the st. James women take heart project. Circulation 2010; 122:130.",
"     </a>",
"    </li>",
"    <li>",
"     Dennis, C. Rehabilitation of patients with coronary artery disease. In: Heart Disease: A Textbook of Cardiovascular Medicine, 4, Braunwald, E (Ed), Saunder, Philadelphia 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/23\">",
"      McElroy PA, Janicki JS, Weber KT. Cardiopulmonary exercise testing in congestive heart failure. Am J Cardiol 1988; 62:35A.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Sports Medicine. ACSM's Resource Manual for Guidelines for Exercise Testing and Prescription, Wolters Kluwer/Lippincott Williams &amp; Wilkins, Philadelphia 2010.",
"    </li>",
"    <li>",
"     Goodman J. Assessment of exercise capacity and principles of exercise prescription. In: Exercise and the Heart in Health and Disease, Shephard RJ, Miller HS (Eds), Marcel Dekker, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3687/abstract/26\">",
"      Reddy HK, Weber KT, Janicki JS, McElroy PA. Hemodynamic, ventilatory and metabolic effects of light isometric exercise in patients with chronic heart failure. J Am Coll Cardiol 1988; 12:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1475 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3687=[""].join("\n");
var outline_f3_38_3687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25194153\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TESTING PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Maximal heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Peak exercise capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anaerobic threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rating of perceived exertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INDICATIONS FOR DISCONTINUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MONITORING DURING EXERCISE REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25194153\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1475\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1475|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/13/8414\" title=\"figure 1\">",
"      Graded benefit of fitness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/41/30366\" title=\"figure 2\">",
"      Response to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/37/605\" title=\"figure 3A\">",
"      Heart rate and VO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/45/7902\" title=\"figure 3B\">",
"      Exercise in HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1475|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/48/19211\" title=\"table 1\">",
"      Absolute contraindications to exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/17/39195\" title=\"table 2\">",
"      Relative contraindications to exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/13/20699\" title=\"table 3\">",
"      Rating of perceived exertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/56/19340\" title=\"table 4\">",
"      Indications for discontinuation of exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 5\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17705?source=related_link\">",
"      Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=related_link\">",
"      Efficacy of cardiac rehabilitation in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/2998?source=related_link\">",
"      Exercise in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_38_3688="Induction immunosuppression following lung transplantation";
var content_f3_38_3688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Induction immunosuppression following lung transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3688/contributors\">",
"     Pamela J McShane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3688/contributors\">",
"     Sangeeta Bhorade, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3688/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3688/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/38/3688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22644993\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major accomplishments of the first successful lung transplantation in 1963 was the prevention of allograft rejection by using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and Cobalt-60 irradiation to suppress the recipient immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/1\">",
"     1",
"    </a>",
"    ]. Since then, great progress has been made in developing immunosuppression regimens to prevent acute and chronic rejection (bronchiolitis obliterans syndrome) of the lung allograft and to reduce the risk of opportunistic infection, a major side effect of immunosuppression.",
"   </p>",
"   <p>",
"    The protocols for immunosuppressive therapy following lung transplantation can be divided into three general categories: induction, maintenance, and treatment of rejection. Strategies for induction of immunosuppression in the lung transplant recipient will be reviewed here. Maintenance immunosuppression, the immunology of solid organ transplantation, and the diagnosis and treatment of acute and chronic lung transplant rejection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link\">",
"     \"Maintenance immunosuppression following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link\">",
"     \"Evaluation and treatment of acute lung transplant rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90189474\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three general principles govern immunosuppressive therapy following lung transplantation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first principle is that immune reactivity and the tendency toward graft rejection are highest in the first six months after graft implantation and decrease with time. Thus, most regimens employ the highest intensity of immunosuppression immediately after surgery and decrease the intensity of therapy over the first year, eventually settling on the lowest maintenance levels of immunosuppression that are compatible with preventing graft rejection.",
"     </li>",
"     <li>",
"      The second principle is that using low doses of several drugs with non-overlapping toxicities is preferable to higher (and more toxic) doses of fewer drugs whenever feasible. Combination regimens also help to block the many components of the complex immunological cascade that leads to allograft rejection.",
"     </li>",
"     <li>",
"      The third principle is to avoid over-immunosuppression, because it leads to undesirable adverse effects, such as susceptibility to infection and malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"       \"Infection in the solid organ transplant recipient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"       \"Development of malignancy following solid organ transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The immunosuppressive strategies used in lung transplantation have capitalized on the experiences with transplantation of other solid organs. However, there is no consensus regarding the optimal regimen for immunosuppression following lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, none of the immunosuppressive medications are approved by the Food and Drug Administration for use in lung transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21538944\">",
"    <span class=\"h1\">",
"     INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy is the brief utilization of a potent immunosuppressive agent in the immediate post-transplant period to reduce the initial robust immune response of T cells to the transplanted organ. Induction agents focus on depletion of T cells and interruption of T cell activation and proliferation, as T cells are the primary mediators of rejection. T cell recognition of antigens on the transplanted lung initiates calcineurin-mediated stimulation of the transcription, translation, and secretion of interleukin-2 (IL-2), an essential growth factor for T-cell proliferation. Interruption of IL-2 activity suppresses T cell proliferation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Induction agents can be classified into two groups: monoclonal agents (eg, interleukin-2 [IL-2] antagonists, muromonab-CD3, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ) and polyclonal agents (eg, anti-lymphocyte and anti-thymocyte globulins) (",
"    <a class=\"graphic graphic_table graphicRef74258 \" href=\"UTD.htm?21/36/22093\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The administration of high-dose glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    500 to 1000 mg intravenous) intraoperatively just before perfusion of the lung allograft is designed to reduce the risk of reperfusion injury. It is generally not considered part of induction therapy, although it probably contributes to the initial immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38697?source=see_link&amp;anchor=H14#H14\">",
"     \"Lung transplantation: Procedure and postoperative management\", section on 'Immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1227773\">",
"    <span class=\"h2\">",
"     Indications and contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of induction therapy remains controversial in lung transplantation although an increasing number of transplant programs, including ours, are using some form of induction therapy. According to the International Society for Heart and Lung Transplantation (ISHLT) registry, the use of induction therapy for lung transplantation has increased from 24 percent in 1997 to 62 percent in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some programs routinely use induction therapy, except in patients with contraindications, and others limit use of induction therapy to highly sensitized patients (eg, those who have preformed panel reactive antibodies [PRA] to the donor MHC antigens and African American recipients).",
"   </p>",
"   <p>",
"    Induction therapy is generally avoided in older patients (&gt;65 years) and patients who are at higher risk for infection (eg, CMV serostatus of",
"    <span class=\"nowrap\">",
"     +donor/-recipient).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2536653\">",
"    <span class=\"h2\">",
"     Induction agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information regarding mechanism of action, dosing, monitoring, and side effects are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef74258 \" href=\"UTD.htm?21/36/22093\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21538958\">",
"    <span class=\"h3\">",
"     Basiliximab/daclizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    and daclizumab are chimeric",
"    <span class=\"nowrap\">",
"     murine/human",
"    </span>",
"    monoclonal antibody preparations that are specific for and bind with high affinity to the alpha subunit of the interleukin-2 receptor (IL-2R, CD25) on activated T cells. Thus, these agents inhibit IL-2 mediated proliferation and differentiation of T cells, but do not deplete them. Basiliximab contains a greater proportion of murine antibody than daclizumab and also has a shorter half-life and lower receptor saturation than daclizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/3\">",
"     3",
"    </a>",
"    ]. Induction therapy with an IL-2R-antagonist was used in 42 percent of lung transplants performed from January 2002 to June 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       Basiliximab",
"      </a>",
"      is administered intraoperatively or immediately following lung transplant and again on the fourth posttransplant day (",
"      <a class=\"graphic graphic_table graphicRef74258 \" href=\"UTD.htm?21/36/22093\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/4\">",
"       4",
"      </a>",
"      ]. The dose for adults and children weighing over 35 kg is 20 mg, infused intravenously over 20 to 30 minutes.",
"     </li>",
"     <li>",
"      Daclizumab is no longer being manufactured in the United States, and it is unclear what its availability will be in the future [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/5\">",
"       5",
"      </a>",
"      ]. Dosing information is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef74258 \" href=\"UTD.htm?21/36/22093\">",
"       table 1",
"      </a>",
"      ). When available, the first dose of daclizumab is administered preoperatively or immediately following transplantation; the usual dose is 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infused intravenously over 15 minutes and repeated every 2 weeks for a total",
"      <sup>",
"      </sup>",
"      of five doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Being humanized, these monoclonal antibodies",
"    <sup>",
"    </sup>",
"    are generally well tolerated and do not cause the cytokine release syndrome typical of muromonab-CD3 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    . However, severe, noncardiac pulmonary edema occurred two days after renal transplantation in three patients who were given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21538972\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (Campath-1H) is a humanized preparation of monoclonal rat antibodies directed toward the CD52 antigen that is present on virtually all lymphocytes (both T and B cells). Alemtuzumab leads to depletion of T cells through complement-mediated and direct cellular cytotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/7\">",
"     7",
"    </a>",
"    ]. Alemtuzumab has been used in the treatment of rheumatoid arthritis, lymphoid malignancies, graft-versus-host disease, and bone marrow transplantation. It was first used as an induction agent in solid organ transplantation in 1998 and was used as an induction agent in approximately 10 percent of lung transplantations performed between January 2002 and June 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    for induction of immunosuppression is 30 mg infused over two hours (",
"    <a class=\"graphic graphic_table graphicRef74258 \" href=\"UTD.htm?21/36/22093\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/9\">",
"     9",
"    </a>",
"    ]. Like OKT3, alemtuzumab also causes a cytokine storm reaction with the first dose. This reaction is more modest than that seen with OKT3 and well-treated by preemptive administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously (",
"    <a class=\"graphic graphic_table graphicRef52276 \" href=\"UTD.htm?1/32/1547\">",
"     table 2",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    50 mg orally or intravenously, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    500 to 1000 mg orally 30 minutes prior to initiation of alemtuzumab infusion. The prevention and management of acute infusion reactions to alemtuzumab are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H40#H40\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Alemtuzumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lymphopenia that results from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    is profound and long lasting; T cell levels (both CD4 and CD8) may remain significantly depressed for as long as 3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/10\">",
"     10",
"    </a>",
"    ]. Because the target CD52 antigen is also present on B cells, alemtuzumab leads to B cell lymphopenia as well, although of a shorter time period, typically about three months. Use of alemtuzumab for induction or treatment of acute rejection has been noted to be an independent risk factor for opportunistic infection in a large study of 547 organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/11\">",
"     11",
"    </a>",
"    ]. Diffuse alveolar hemorrhage has been reported with the use of alemtuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25845309\">",
"    <span class=\"h3\">",
"     Anti-thymocyte globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     anti-lymphocyte/anti-thymocyte",
"    </span>",
"    globulins are polyclonal immunoglobulin preparations created from horses (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/40/20102?source=see_link\">",
"     horse antithymocyte globulin",
"    </a>",
"    , equine ATG, eATG, Atgam) or rabbits (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"     rabbit antithymocyte globulin",
"    </a>",
"    , rabbit ATG, rATG, Thymoglobulin) with antibodies against human T cells. Antithymocyte globulins act through the Fc receptor and other proteins on the surface of T cells to deplete cytotoxic T cells. These agents are used in less than 15 percent of induction regimens for lung transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical regimen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"     rabbit antithymocyte globulin",
"    </a>",
"    (Thymoglobulin) is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered intravenously on day one and then two or three additional doses given 24 hours apart (",
"    <a class=\"graphic graphic_table graphicRef74258 \" href=\"UTD.htm?21/36/22093\">",
"     table 1",
"    </a>",
"    ). The initial dose is infused over at least six hours through a high-flow vein; subsequent doses are administered over at least four hours. In general, lymphocyte subsets (CD3 &gt;5 percent) are followed to determine whether to administer the subsequent daily doses. The typical regimen for administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/40/20102?source=see_link\">",
"     horse antithymocyte globulin",
"    </a>",
"    (Atgam) is intravenous administration of 5 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for the first 1 to 14 days following lung transplantation.",
"   </p>",
"   <p>",
"    Many patients have an acute reaction of fever, rigors, myalgias, rash, and tachycardia to initial administration. Premedication with glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and an antihistamine can prevent or reduce infusion-related symptoms. Patients are commonly premedicated with glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    125 mg intravenously), antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    50 mg orally or intravenously), and antipyretics (eg, acetaminophen 1g orally) one hour prior to anti-thymocyte globulin.",
"   </p>",
"   <p>",
"    In addition to infusion-related symptoms, antithymocyte globulin therapy is associated with leukopenia, thrombocytopenia, immune-complex-mediated glomerulonephritis, and rarely, serum sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22644714\">",
"    <span class=\"h3\">",
"     Muromonab-CD3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muromonab-CD3 (OKT3) is a mouse monoclonal antibody that has been used as an induction agent to prevent acute lung transplant rejection since the 1980s. However, it was used in less than 10 percent of lung transplants in 2009 and is not used in our transplantation program [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ]. Most experts avoid using the drug for induction therapy in lung transplantation due to its side effect profile.",
"   </p>",
"   <p>",
"    OKT3 binds to the T cell receptor-CD3 complex. This binding causes a reversible antigenic modification of the CD3 complex, leading to depletion of T cells, except for relative sparing of T regulatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link&amp;anchor=H5#H5\">",
"     \"The adaptive cellular immune response\", section on 'Structure of the T cell receptor CD3 complex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The regimen for administration of OKT3 has been to give an intravenous dose of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for patients weighing 80 kg or more and 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for patients less than 80 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/14\">",
"     14",
"    </a>",
"    ]. Dosing information is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef74258 \" href=\"UTD.htm?21/36/22093\">",
"     table 1",
"    </a>",
"    ). The first dose is administered immediately following transplantation and is repeated daily for five to seven days, as guided by daily measurement of lymphocyte subsets and total lymphocyte counts. The dose is held for a CD3+ lymphocyte count &lt;5 percent or a total lymphocyte count &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    A massive first-dose cytokine-release syndrome consisting of fever, rigors, nausea, vomiting, diarrhea, and in some severe cases, hemodynamic instability is a well-described complication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/15\">",
"     15",
"    </a>",
"    ]. For this reason, patients are commonly premedicated with glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    125 mg intravenously), antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    50 mg orally or intravenously), and antipyretics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    1g orally) one hour prior to OKT3 dosing.",
"   </p>",
"   <p>",
"    Other side effects associated with OKT3 include pulmonary edema in patients who are fluid overloaded at the time of administration and aseptic meningitis, which has been seen in 3 to 5 percent of patients receiving OKT3 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Although OKT3 is one of the most potent immunosuppressives available, development of neutralizing antibodies to OKT3 limit prolonged use [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/18\">",
"     18",
"    </a>",
"    ]. Other side effects include mild elevations in pulmonary artery systolic pressure, mild reduction in oxygenation, and pyrexia that are self-limited, easily treated, and resolve within 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21538979\">",
"    <span class=\"h2\">",
"     Efficacy of induction therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90189642\">",
"    <span class=\"h3\">",
"     Effect on survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superiority of one induction agent over another regarding graft and recipient survival varies from one study to another, but use of an induction agent is generally superior to no induction. According to data from the ISHLT registry on 5626 adult lung recipients, the use of any induction therapy compared with no induction therapy is associated with a slight but statistically significant improvement in survival [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the difference between the groups is not apparent until at least a year following transplant (for a figure showing survival information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled Survival by Induction Usage and the slide Reported rejection between discharge and 1-year at:",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a more rigorous, but still retrospective, analysis of the ISHLT data on 3970 adult lung recipients, graft survival at four years was better among those who received an IL-2 receptor antagonist (64 percent) than those treated with antithymocyte globulin (60 percent) or no induction (57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/20\">",
"     20",
"    </a>",
"    ]. The survival advantage was independent of other variables that might affect survival.",
"   </p>",
"   <p>",
"    In a single center study, 44 lung recipients were randomly assigned to conventional immunosuppression with rat antithymocyte (RATG) induction or conventional immunosuppression without induction (control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/21\">",
"     21",
"    </a>",
"    ]. There was no difference in graft survival between the groups at eight years (RATG: 36 percent; control: 23 percent; p = 0.48). (See",
"    <a class=\"local\" href=\"#H25845309\">",
"     'Anti-thymocyte globulin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A retrospective analysis examined outcomes among 336 lung transplant recipients who received induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , thymoglobulin, or daclizumab, or received no induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/9\">",
"     9",
"    </a>",
"    ]. Survival was greater in the alemtuzumab group compared with daclizumab or no induction, but not different from thymoglobulin. (See",
"    <a class=\"local\" href=\"#H21538972\">",
"     'Alemtuzumab'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25845309\">",
"     'Anti-thymocyte globulin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21538958\">",
"     'Basiliximab/daclizumab'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90189673\">",
"    <span class=\"h3\">",
"     Effect on rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the effect of induction therapy on the frequency of acute rejection are conflicting. The strongest data in favor of the IL-2 antagonists comes from the ISHLT registry. Among 5626 lung recipients, the IL-2 antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    , daclizumab) were associated with a lower percentage of recipients developing rejection in the first year after transplantation when compared with no induction (32 versus 37 percent, p&lt;0.0002), use of polyclonal antithymocyte globulin (ATG) therapy (32 versus 38 percent, p&lt;0.0099), or use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (32 versus 39 percent, p&lt;0115) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, in a retrospective analysis of 27 lung recipients, at six months daclizumab was associated with a slight decrease in rejection compared with no induction therapy (p&lt;0.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other case series and a randomized trial have not confirmed a benefit to interleukin-2 receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/5,22-24\">",
"     5,22-24",
"    </a>",
"    ]. In a randomized trial of 50 lung recipients, no difference in acute or chronic rejection was found between the induction agents, daclizumab and antithymocyte globulin (ATG) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/5\">",
"     5",
"    </a>",
"    ]. In a retrospective series of 335 lung recipients, episodes of acute cellular rejection occurred during two years of follow-up in 74 percent of those given ATG and 100 percent of those given daclizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, a retrospective study of 157 recipients found that 38 percent of those given ATG had their first episode of rejection in the first 100 days following transplant, compared with 60 percent of those given basiliximab [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 336 lung transplant recipients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    was associated with modestly greater freedom from acute or chronic rejection at five years compared with thymoglobulin, daclizumab or no induction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90189766\">",
"    <span class=\"h2\">",
"     Choosing an agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal induction regimen for lung transplantation is not known, and choosing between the agents requires a balance between preventing or reducing allograft rejection and limiting side effects of immunosuppression, such as infusion reactions and opportunistic infections. Taken together, data from a large database, case series and small trials suggest that IL-2 antagonists are associated with a comparable to slightly better survival, freedom from rejection, and drug tolerability compared with other induction agents or no induction. (See",
"    <a class=\"local\" href=\"#H21538979\">",
"     'Efficacy of induction therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based on data from the International Society for Heart and Lung Transplantation (ISHLT) registry, clinical practice has gradually moved away from polyclonal antithymocyte globulin (ATG) in favor of monoclonal preparations such as the interleukin-2 receptor (IL-2) antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"     2",
"    </a>",
"    ]. IL-2R antagonists were used in 37 percent of lung transplantations performed between January 2002 and June 2010, in contrast with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     anti-lymphocyte/anti-thymocyte",
"    </span>",
"    globulin, which were used in 5 and 12 percent of recipients, respectively (for a figure showing induction immunosuppression information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled &ldquo;Adult Lung Recipients: Induction immunosuppression&rdquo; at:",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15072184\">",
"    <span class=\"h1\">",
"     PREVENTION OF OPPORTUNISTIC INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opportunistic infection is a major side effect of immunosuppression for organ transplantation. Regimens for prophylaxis for bacterial, fungal and viral infections post transplant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022736#H1627022736\">",
"     \"Bacterial infections following lung transplantation\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022774#H1627022774\">",
"     \"Bacterial infections following lung transplantation\", section on 'Vaccination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H22#H22\">",
"     \"Fungal infections following lung transplantation\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90189076\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goals for future induction regimens include a better understanding of the optimal balance between promotion of tolerance and prevention of rejection, improved methods for matching the intensity of immunosuppression with an individual&rsquo;s risk of acute or chronic rejection, and better methods for assessment of the net effect of combination immunosuppression regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3688/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. As an example, it is not known whether extensive T cell depletion with induction therapy may actually lead to reconstitution with a greater proportion of alloreactive T cells (promote rejection) than T regulatory cells (promote tolerance).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21539084\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy refers to the brief utilization of a potent immunosuppressive agent in the immediate post-transplant period to reduce the initial robust immune response to the transplanted organ. The decision to use specific induction immunosuppression and the choice of agent vary according to transplant center experience and recipient characteristics (eg, panel reactive antibodies level and individual drug tolerability); there is no clear consensus regarding the optimal regimen. (See",
"      <a class=\"local\" href=\"#H21538944\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rationale behind induction immunosuppression is two-fold: induction regimens are designed to promote early and potent immunosuppression, as the tendency toward graft rejection is highest early (within the first three to six months) after graft implantation, and potent induction may enable a less potent and less toxic maintenance regimen to be successful. (See",
"      <a class=\"local\" href=\"#H90189474\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The induction agents that are used for lung transplantation include the interleukin-2 receptor (IL-2R) antagonists, the anti-T and B cell antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      , and antithymocyte globulin; muromonab-CD3 is no longer available. Information about the administration of these agents and their potential adverse effects is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef74258 \" href=\"UTD.htm?21/36/22093\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2536653\">",
"       'Induction agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the time of lung transplantation, we suggest administering induction therapy, based on better survival statistics in a large registry database (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among induction agents, we prefer one of the interleukin-2 (IL-2) receptor antagonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      ), rather than other induction agents. This is based on evidence that the IL-2 receptor antagonists (basiliximab and daclizumab) are associated with comparable or slightly better outcomes and better tolerability compared with the other options. In addition, the IL-2 receptor antagonists have a lower toxicity. (See",
"      <a class=\"local\" href=\"#H21538958\">",
"       'Basiliximab/daclizumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21538979\">",
"       'Efficacy of induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muromonab-CD3 (OKT3), a mouse monoclonal antibody that binds the T cell receptor-CD3 complex, is not used for induction therapy in lung transplant recipients due to its high adverse effect profile. (See",
"      <a class=\"local\" href=\"#H22644714\">",
"       'Muromonab-CD3'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opportunistic infection is a major side effect of immunosuppression for organ transplantation. Regimens for prophylaxis against bacterial, fungal and viral infections post transplant are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022736#H1627022736\">",
"       \"Bacterial infections following lung transplantation\", section on 'Prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022774#H1627022774\">",
"       \"Bacterial infections following lung transplantation\", section on 'Vaccination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H22#H22\">",
"       \"Fungal infections following lung transplantation\", section on 'Prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maintenance immunosuppression following lung transplantation is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link\">",
"       \"Maintenance immunosuppression following lung transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis and treatment of acute and chronic lung transplant rejection are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link\">",
"       \"Evaluation and treatment of acute lung transplant rejection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"       \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/1\">",
"      Blumenstock DA, Lewis C. The first transplantation of the lung in a human revisited. Ann Thorac Surg 1993; 56:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/2\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011. J Heart Lung Transplant 2011; 30:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/3\">",
"      Lake KD. Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection. Semin Respir Crit Care Med 2001; 22:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/4\">",
"      Swarup R, Allenspach LL, Nemeh HW, et al. Timing of basiliximab induction and development of acute rejection in lung transplant patients. J Heart Lung Transplant 2011; 30:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/5\">",
"      Mullen JC, Oreopoulos A, Lien DC, et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007; 26:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/6\">",
"      Bamgbola FO, Del Rio M, Kaskel FJ, Flynn JT. Non-cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients. Pediatr Transplant 2003; 7:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/7\">",
"      Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000; 12:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/8\">",
"      Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/9\">",
"      Shyu S, Dew MA, Pilewski JM, et al. Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant 2011; 30:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/10\">",
"      Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006; 81:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/11\">",
"      Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/12\">",
"      Sachdeva A, Matuschak GM. Diffuse alveolar hemorrhage following alemtuzumab. Chest 2008; 133:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/13\">",
"      Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/14\">",
"      Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001; 20:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/15\">",
"      Chatenoud L, Baudrihaye MF, Kreis H, et al. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/16\">",
"      Costanzo-Nordin MR. Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction. Transplant Proc 1993; 25:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/17\">",
"      Figg WD. Aseptic meningitis associated with muromonab-CD3. DICP 1991; 25:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/18\">",
"      Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/19\">",
"      Wain JC, Wright CD, Ryan DP, et al. Induction immunosuppression for lung transplantation with OKT3. Ann Thorac Surg 1999; 67:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/20\">",
"      Hachem RR, Edwards LB, Yusen RD, et al. The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clin Transplant 2008; 22:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/21\">",
"      Hartwig MG, Snyder LD, Appel JZ 3rd, et al. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant 2008; 27:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/22\">",
"      Garrity ER Jr, Villanueva J, Bhorade SM, et al. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001; 71:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/23\">",
"      Hachem RR, Chakinala MM, Yusen RD, et al. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant 2005; 24:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/24\">",
"      Burton CM, Andersen CB, Jensen AS, et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 2006; 25:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/25\">",
"      Floreth T, Bhorade SM, Ahya VN. Conventional and novel approaches to immunosuppression. Clin Chest Med 2011; 32:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3688/abstract/26\">",
"      Wieland E, Olbricht CJ, S&uuml;sal C, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010; 32:560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4661 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3688=[""].join("\n");
var outline_f3_38_3688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21539084\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22644993\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90189474\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21538944\">",
"      INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1227773\">",
"      Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2536653\">",
"      Induction agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21538958\">",
"      - Basiliximab/daclizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21538972\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25845309\">",
"      - Anti-thymocyte globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22644714\">",
"      - Muromonab-CD3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21538979\">",
"      Efficacy of induction therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90189642\">",
"      - Effect on survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H90189673\">",
"      - Effect on rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90189766\">",
"      Choosing an agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15072184\">",
"      PREVENTION OF OPPORTUNISTIC INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90189076\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21539084\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/36/22093\" title=\"table 1\">",
"      Induction agents for lung transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/32/1547\" title=\"table 2\">",
"      Steroid compound dose equiv",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=related_link\">",
"      Evaluation and treatment of acute lung transplant rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38697?source=related_link\">",
"      Lung transplantation: Procedure and postoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=related_link\">",
"      Maintenance immunosuppression following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_38_3689="Genetic association studies: Principles and applications";
var content_f3_38_3689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic association studies: Principles and applications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3689/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3689/contributors\">",
"     John Attia, MD, PhD, FRCPC, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3689/contributors\">",
"     Gordon Guyatt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3689/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3689/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/38/3689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in the genetic determinants of disease originated with Gregor Mendel's observations on the genetics of the pea in the 1860s. Subsequent studies have identified many of the genes responsible for \"Mendelian\" diseases, conditions that follow a clear familial pattern. However, diseases inherited in a Mendelian fashion (eg, Huntington disease and cystic fibrosis) are rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More recently, the Human Genome Project has generated growing interest in genetic contribution to \"complex\" diseases. Such diseases combine some familial predisposition with a large environmental contribution. Examples include cardiovascular disease, diabetes, asthma, cancer, and obesity.",
"   </p>",
"   <p>",
"    This topic will discuss the principles and clinical applications of genetic association studies in the elucidation of the genetic basis for common diseases with complex genetic components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC ASSOCIATION STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic association studies are analogous to traditional epidemiologic association studies. Instead of seeking association between traditional risk variables (eg, hypertension) and disease outcomes (eg, stroke), a genetic association study looks for an association between a genetic variable and a specified condition. The genetic variant most commonly studied is a single nucleotide polymorphism (SNP, pronounced \"snip\"). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link\">",
"     \"Overview of genetic variation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual study design for association studies is case-control or nested case-control, where controls are selected from the general population. These association studies have exploded in number in the medical literature over the last few years. Between 2007 and 2009, genome-wide association studies identified nearly 1000 SNPs associated with a range of human traits and common diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/1\">",
"     1",
"    </a>",
"    ]. By March 2011, that number had risen to almost 4000 SNPs for over 200 conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other designs, using family-based data (eg, pedigrees, parent-offspring trios, or sibling pairs) are becoming less popular due to difficulties in obtaining sufficient sample size and the need for specialized statistical methods for analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Candidate gene approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier gene association studies employed a \"candidate\" gene approach in which a genetic variant of interest was selected on the basis of the known biology of a disease. The genetic variant may be of interest because of its presumed biologic function, or association with a disease in previous studies. In this approach, one or a small number of known variants are genotyped, usually by PCR methods, in a number of cases and controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genome-wide approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genome-wide association studies (GWAS, pronounced \"gee-wass\") test hundreds of thousands of candidate genes simultaneously (",
"    <a class=\"graphic graphic_figure graphicRef54220 \" href=\"UTD.htm?41/33/42521\">",
"     figure 1",
"    </a>",
"    ). GWAS use microarray technology. Recent technological advances with microarrays have enabled researchers to genotype an individual for between 500,000 and 1 million SNPs on a platform no bigger than a microscope slide.",
"   </p>",
"   <p>",
"    The principle behind microarrays is that DNA from an individual is hybridized against a short oligonucleotide probe (ie, DNA sequence) that is immobilized on a surface. Sequences are chosen to capture the regions with the most variation in the genome. If the individual has the DNA sequence that is complementary to that probe, the DNA binds and is detected (",
"    <a class=\"graphic graphic_figure graphicRef52164 \" href=\"UTD.htm?17/48/18177\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GWAS are increasingly popular, with 24 studies in 2003, increasing to 1010 in 2010; this represents 3 percent of all genetic association studies reported in 2003 but &gt;12 percent in 2010.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMMON DISEASE-COMMON VARIANT HYPOTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic assumption regarding genetic determinants of complex disease is that common variants in many genes will each lead to a small rise (or fall) in the risk of disease, and that the overall risk of disease is determined by the combination of multiple variants and environmental exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/4\">",
"     4",
"    </a>",
"    ]. The single nucleotide polymorphisms (SNPs) chosen for inclusion on microarrays are usually the more common variants in the population.",
"   </p>",
"   <p>",
"    The competing theory is \"common disease-rare variant\" in which it is anticipated that most common disease will be due to multiple rare variants (&lt;1 percent), perhaps even unique mutations. If this is the case, GWA would be less useful, and one would need to move to whole genome sequencing to detect these associations. The technology is advancing quickly, and it is anticipated that whole-genome sequencing will become competitively priced, and hence more common, within the next few years.",
"   </p>",
"   <p>",
"    In reality, the dichotomy between common and rare variants is not absolute, and results from one will likely complement the other. As an example, sequencing of the cystic fibrosis gene reveals that one major allele, Delta F508, accounts for 67 percent of disease in Europe, but the remainder is due to hundreds of rarer disease",
"    <span class=\"nowrap\">",
"     alleles/mutations",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the last few years, GWAS have led to the successful identification of many genes involved in complex disease, such as coronary artery disease, type 2 diabetes, stroke, multiple sclerosis, breast cancer, bipolar disorder, rheumatoid arthritis, and Alzheimer's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/6-14\">",
"     6-14",
"    </a>",
"    ]. These studies largely confirm the concept that multiple genes, each conferring small relative risks (ie, 1.2-1.8), collectively contribute to increased disease risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Missing heritability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite many successes, GWAS overall have not explained as much of the variance in complex traits as was originally expected. Heritability studies look at the variance in a trait and use family relationships (eg, twins and siblings) to partition how much of the variance is due to genetic factors and how much is due to environmental factors. As an example, studies have estimated that height is 80 to 90 percent \"heritable,\" but GWAS and meta-analyses of GWAS on height have turned up more than 40 genes, accounting for less than 5 percent of the variance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This disappointing result has led to several hypotheses about factors that may account for the \"missing heritability\" [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some of the variation may be explained by rare alleles that will only be detected by whole genome sequencing, rather than SNPs.",
"     </li>",
"     <li>",
"      Estimates of heritability are complex and may have been interpreted simplistically. High heritability does not necessarily mean genetic determination or genes of large effect, but may reflect high shared environment as well [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some of the variation may be explained by copy number variants (CNVs). CNVs are polymorphisms that consist of deletions or duplications of whole segments of DNA, spanning at least 1,000 bases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/19\">",
"       19",
"      </a>",
"      ]. Although CNVs can show association for some diseases where SNPs have not yielded any signal (eg, autism) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/20\">",
"       20",
"      </a>",
"      ], it seems unlikely that common CNVs will explain most of the unaccounted heritability for the majority of complex traits [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/21\">",
"       21",
"      </a>",
"      ]. An investigation of the association of CNVs with eight complex diseases found that most CNV signals were in areas that had already been highlighted by SNP associations, and most CNVs were \"tagged\" by SNPs [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analysis methods for SNP data are still being developed. Current methodology may not be adequate to detect",
"      <span class=\"nowrap\">",
"       gene/gene",
"      </span>",
"      interactions (epistasis). This is particularly true if each genetic variant alone shows no effect but shows an effect in the presence of the other variant.",
"     </li>",
"     <li>",
"      Heritability may be accounted for by epigenetic changes, for example, methylation of DNA or modification of histone proteins. There is increasing evidence that these non-DNA changes can also be passed on from generation to generation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others, however, maintain that there is no &ldquo;missing heritability&rdquo; and that with enough SNPs, much of the variance in a trait can be explained. For example, one model using just under 30,000 SNPs could account for 45 percent of the variance in height [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/24\">",
"     24",
"    </a>",
"    ]. Fitting all genotyped SNPs explains a substantial portion of the heritability for such complex phenotypes as height, BMI, von Willebrand factor levels and QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENOME-WIDE ASSOCIATION STUDIES (GWAS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most GWAS are case-control studies, where a group of cases and a group of separate controls are gathered, DNA is isolated and microarray data is obtained on each individual. The case-control design facilitates large sample sizes and therefore power, which is particularly important for detecting potentially small genetic effects.",
"   </p>",
"   <p>",
"    At the most basic level, the distribution of the three genotypes for each single nucleotide polymorphism (SNP) (AA, Aa, aa) is compared between cases and controls using a Chi-square test. This is repeated over and over for each of the 500,000 or more SNPs on the array. GWAS have also been performed using longitudinal cohorts, with cases and controls \"nested\" within the cohort.",
"   </p>",
"   <p>",
"    Despite the issue of \"missing heritability,\" GWAS have had some notable successes, identifying genes of large effect. An example is the relationship between Complement Factor H Y402H polymorphism and age-related macular degeneration (AMD). This polymorphism is involved in regulation of the alternate complement pathway that results in increased inflammation. Individuals with one allele coding for a histidine substitution for tyrosine in position 402 of the CFH protein (CFH Y402H) on chromosome 1 are at increased risk for AMD. Meta-analysis indicates a possible multiplicative model in that each copy of the C allele at this locus (coding for histidine) increases the risk of AMD by approximately 2.5-fold compared to the T allele (ie, the TC heterozygote group has an odds ratio (OR) for AMD of 2.5 and the CC homozygote has an odds ratio of approximately 6 relative to the TT genotype group) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other GWAS results have shed light on the pathogenesis of a disease process (eg, the role of melatonin in type 2 diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     JUDGING STUDY VALIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is increasingly necessary for physicians to become familiar with GWAS data and how to gauge validity of these studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Potential biases",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple potential biases for case-control studies in traditional epidemiology. The potential for bias is less, though not absent, in genetic studies. In contrast to most environmental exposures, the genetic \"exposure\" is not chosen by the participant, doesn't vary with age or calendar year, is not subject to recall bias, and is not influenced by the disease or treatment.",
"   </p>",
"   <p>",
"    One potential bias that cannot be avoided, however, is survivor bias, in that those who are included in a case-control study are those who have survived the initial \"insult\" (",
"    <a class=\"graphic graphic_figure graphicRef50171 \" href=\"UTD.htm?30/15/30966\">",
"     figure 3",
"    </a>",
"    ). As an example, in a study of stroke, results may differ between a case-control and cohort GWAS if certain genes are associated with initial stroke severity, causing early mortality before recruitment into a case-control study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Validity framework",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many groups have published guidelines for critical appraisal of genetic association studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. One framework, from the \"Users' Guides to the Medical Literature\" series, follows [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Was the disease phenotype properly defined and accurately recorded by someone blind to the genetic information?",
"     </li>",
"     <li>",
"      Have any potential differences between disease and non-disease groups, particularly ancestry, been properly addressed?",
"     </li>",
"     <li>",
"      Was measurement of the genetic variants unbiased and accurate?",
"     </li>",
"     <li>",
"      Do the genotype proportions observe Hardy-Weinberg equilibrium (HWE)?",
"     </li>",
"     <li>",
"      Have the investigators adjusted for multiple comparisons?",
"     </li>",
"     <li>",
"      Are the results consistent with other studies?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Phenotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;What may seem like a unique disease (eg, ischemic stroke), may be a heterogeneous group of diseases (eg, large vessel stroke, lacunar stroke, and embolic stroke), or may be variously defined (eg, clinical signs only, or",
"    <span class=\"nowrap\">",
"     CT/MRI",
"    </span>",
"    imaging confirmation). Investigators may selectively report only the disease definition or subgroup that yields a significant association [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, an apparent single disease entity may represent genetically separate but clinically similar diseases (\"genetic heterogeneity\"), as seen with epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/34\">",
"     34",
"    </a>",
"    ]. Including diseases with different genetic backgrounds may obscure a true genetic association.",
"   </p>",
"   <p>",
"    To avoid bias, those who are doing the phenotyping should be blind to the results of the genotyping and vice versa. The possibility of bias is greater for candidate gene studies where single nucleotide polymorphisms (SNPs) are typed manually in contrast to GWAS in which the genotype identification is automated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ancestry and comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although genetic association studies are less prone to traditional confounding than other case control studies, there are two potential sources of bias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ethnicity or racial mix &mdash; This particular form of confounding, referred to as \"population stratification,\" occurs when disease and non-disease populations include a different",
"      <span class=\"nowrap\">",
"       ethnic/racial",
"      </span>",
"      mix. If the likelihood of developing the condition of interest varies with ancestry, then any SNP with a different allele frequency between ancestral groups will appear to be linked (spuriously) to the disease (",
"      <a class=\"graphic graphic_figure graphicRef78339 \" href=\"UTD.htm?38/36/39496\">",
"       figure 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      As with traditional confounders, the way to correct for this is to measure the confounder and adjust for it in the analysis or to stratify the analysis. Ethnic subgroups may be identified by self-report or by statistical analysis of SNPs themselves [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. As an example, a spurious association between the CYP3A4-V polymorphism and prostate cancer in African-Americans disappeared when results were adjusted for additional genetic markers associated with ancestry in the population studied [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Comorbidities/associated",
"      </span>",
"      phenotypes &mdash; An apparent association between a genotype and condition of interest may represent a direct association between the genotype and another condition, with the disease of interest being linked to this other condition. As an example, two GWAS showed an association between type 2 diabetes and a SNP in the FTO (fat mass and obesity associated) gene [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/7,38\">",
"       7,38",
"      </a>",
"      ]. These studies selected diabetic patients and controls irrespective of their body mass index (BMI); another study that matched diabetic patients and controls on BMI showed no association. Thus, obesity is associated with diabetes and the initial SNP was thought to be linked with diabetes when in fact it was linked with the associated obesity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Accuracy of genotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotyping error is a threat to the validity of genetic association studies. Genotyping errors may arise if there is a problem with the DNA samples or with the technology that is employed to identify alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DNA samples may differ between diseased and non-diseased participants in ways that lead to inaccuracies in genotyping. As an example, in a GWA study for type 2 diabetes, blood used for the control population was stored from a cohort in 1958 while samples from patients with known diabetes were from the present day. The older blood resulted in genotyping errors that led to false positive SNP associations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genotyping error rates vary widely, from &lt;1 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/41\">",
"     41",
"    </a>",
"    ]; rates up to a few percent are common in even the best studies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/42\">",
"     42",
"    </a>",
"    ]. It is common practice for investigators to cull SNPs that do not have a high call rate (eg, 95 to 98 percent). Call rate refers to the percent of DNA samples that can be genotyped. This increases the validity of the data but does not ensure that the genotype information is correct. The genotype may be misidentified as, for example, when one of the alleles in a heterozygote is harder to identify than the other, resulting in a heterozygote being mislabeled a homozygote. Checking for Hardy-Weinberg equilibrium may be one way of detecting genotyping problems. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Hardy-Weinberg equilibrium'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hardy-Weinberg equilibrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the same way that most continuous variables in medicine observe a normal distribution, most allele distributions observe what is called Hardy-Weinberg equilibrium (HWE). The Hardy-Weinberg law states that if there are two alleles (named A and a) at a particular locus, with frequency p and q respectively, then after one generation of random mating, the genotype frequencies of the AA, Aa, and aa groups in the population will be p",
"    <sup>",
"     2,",
"    </sup>",
"    2pq, and q",
"    <sup>",
"     2,",
"    </sup>",
"    respectively. Given that there are only two alleles possible, A or a, then:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      p + q = 1,",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    and",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      p",
"      <sup>",
"       2",
"      </sup>",
"      +2pq + q",
"      <sup>",
"       2",
"      </sup>",
"      = 1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HWE is commonly used as a quality measure. It has become general practice, in a genetic association study, to check whether the allele frequencies at a particular SNP observe HWE proportions. Results are considered to be consistent with HWE when the p-value is &lt;0.05. HWE calculators are available online [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. For a cohort study, HWE should be tested in the whole study population, whereas for a case-control study, it should be tested in the controls, since these are supposedly representative of the general population.",
"   </p>",
"   <p>",
"    However, HWE is non-specific and may be insensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/45\">",
"     45",
"    </a>",
"    ]. Genotyping error and population stratification are two of many factors that may upset HWE proportions. Other factors that may affect HWE include new mutations or a selective advantage of one allele over another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Multiple comparisons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual p-value for judging statistical significance in traditional epidemiological studies (0.05) is intended for a single comparison. The .05 threshold means that a result as extreme or more extreme than the one seen will occur by chance once in 20 times; this is taken as low enough to not be chance and to indicate a significant association. However, if one is looking at 100 SNPs, then by chance alone one might expect 5 SNPs to reach this threshold; in fact there is over a 99 percent chance that at least one will reach this threshold.",
"   </p>",
"   <p>",
"    In GWA studies in which over 500,000 SNPs are tested simultaneously, the possibilities for false-positive are countless. The current consensus is that for such large scale studies, a p-value in the range of 5x10",
"    <sup>",
"     -8",
"    </sup>",
"    (in contrast to the usual 5x10",
"    <sup>",
"     -2",
"    </sup>",
"    ) should be considered the threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential that studies replicate their results, given the large potential for false positive signals. This is commonly done by repeating the study in different populations.",
"   </p>",
"   <p>",
"    There is a growing movement to combine GWAS results using meta-analysis. Most of the genetic associations between SNPs and complex diseases are small in magnitude, and therefore even sizable studies may fail to detect underlying associations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/47\">",
"     47",
"    </a>",
"    ]. Meta-analysis improves the identification of replicable associations and increases precision by increasing power. This is illustrated by studies in Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/48\">",
"     48",
"    </a>",
"    ] and in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HuGE Net website lists many of the meta-analyses performed to date and also hosts the HuGE Navigator, where one can find out what single studies, genome-wide association studies, meta-analyses, and synopses are available [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Replication can also take the form of functional studies in vitro or in animal models. Demonstration by cell culture or mouse mutagenesis that genetic variants can lead to difference in protein level or function can provide powerful support for the effect of genetic variants. Follow-up studies can also provide evidence to support an initial GWAS result, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candidate gene association studies that focus on a few genetic variants that are near the site of the initial GWAS locus",
"     </li>",
"     <li>",
"      Fine mapping studies, involving a denser set of SNPs around the initial GWAS locus or involving resequencing of the entire locus to pick up rare variants",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INTERPRETING GWAS RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators usually report the magnitude of a genetic association using traditional measures of association: relative risks (RRs) in cohort studies, odds ratios (ORs) in case-control studies, and hazard ratios (HRs) in survival analyses that take account of the timing of events.",
"   </p>",
"   <p>",
"    Understanding the magnitude of the risk depends on the genetic model involved. For dominant variant alleles (producing a protein isoform that dominates function), the presence of even one copy (ie, heterozygosity) will result in maximal increase in risk. For recessive variant alleles, both alleles must be present to result in an increase in risk (ie, heterozygotes will not show an increase in risk). In both cases, a single RR, OR or HR describes the magnitude of the association.",
"   </p>",
"   <p>",
"    If the effect of a variant allele is additive, then there is a \"dose-response\" effect: its presence in one gene will lead to an increase in risk, while its presence in both genes will lead to a further increase. There are two possible ways to calculate this further increase: one is to take the square of the risk (variably called the log-additive, per-allele, or multiplicative risk model), and the other is to take two times the risk (called the linear additive model). Recent work in diabetes indicates that most associations seem to follow the log-additive model [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to understand that the magnitude of the effect does not necessarily translate into a causal relationship between the single nucleotide polymorphism (SNP) and the disease. It is possible that the SNP is only a marker for another SNP nearby that is linked (termed \"linkage disequilibrium\") and that is the true causal variant. While linkage disequilibrium does not detract from the potential use of the SNP as a clinical marker, it limits the potential to draw pathophysiologic conclusions from the identified SNP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A framework for translating GWAS results to clinical application has been developed and is presented here [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the genetic association improve predictive power beyond easily measured clinical variables?",
"     </li>",
"     <li>",
"      What are the absolute versus relative genetic effects?",
"     </li>",
"     <li>",
"      Is the risk-associated allele likely to be present in my patient?",
"     </li>",
"     <li>",
"      Is the patient likely better off knowing the genetic information?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues need to be addressed thoughtfully and quickly, particularly given the \"direct-to-consumer\" availability of genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Predictive power",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of single SNPs in complex disease to date has been small (ie, odds ratios in the 1.1-1.6 range). Therefore, there has been interest in combining the effect of many genes into a genetic \"profile\" for greater clinical utility.",
"   </p>",
"   <p>",
"    As an example, in one study, investigators created a profile of 5 SNPs associated with prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/55\">",
"     55",
"    </a>",
"    ]; they found an OR of 1.6 for those who were homozygous or heterozygous for the risk allele at one SNP, and up to 4.5 for those who were homozygous or heterozygous for the risk allele at 4 SNPs. The greater the number of SNPs in each profile, however, the lower the number of people with that combination; hence the increased magnitude of effect is offset by the small number of people to whom that effect is relevant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are rare examples, particularly in the area of pharmacogenomics, where genetic associations may have clinical applications because of their large magnitude. As an example, a SNP in the TPMT gene identifies children with acute leukemia who are at increased risk of a life-threatening adverse event with the chemotherapeutic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/57\">",
"     57",
"    </a>",
"    ]. Genotyping this SNP can avoid substantial harm by substituting an alternative chemotherapeutic agent in those with the high-risk genotype.",
"   </p>",
"   <p>",
"    The most likely short-term clinical application of a genetic association is to provide prognostic information in the context of other known predictors. To be of value, the genetic marker must provide independent predictive power beyond traditional clinical predictive variables (eg, age, sex, smoking status) and beyond easily obtained surrogate measures of familial aggregation, such as family history. This is often not the case, particularly if the genetic polymorphism exerts its effect through a readily measured variable (eg, a gene controlling lipids exerts its effect through increases in LDL).",
"   </p>",
"   <p>",
"    For dichotomous (eg,",
"    <span class=\"nowrap\">",
"     yes/no)",
"    </span>",
"    outcomes, there are a number of statistical tools to quantitate how much predictive power the genetic information adds to existing data. One is to calculate the area under the Receiver Operating Characteristic (ROC) curve, an approach often used for diagnostic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/58\">",
"     58",
"    </a>",
"    ]. An ROC curve plots the true positive rate (sensitivity) on the y-axis against the false positive rate (1-specificity) on the x-axis (",
"    <a class=\"graphic graphic_figure graphicRef82175 \" href=\"UTD.htm?31/56/32653\">",
"     figure 5",
"    </a>",
"    ). An ROC curve with no greater predictive ability than chance would approximate a straight diagonal line from the origin (0, 0) to the upper right hand corner (1.0, 1.0). The area under the curve (AUC) would be 0.5. The visual representation of a perfectly predictive test would be a line that goes straight up the y-axis to 1.0 and then straight across the x-axis to 1.0 and would have an AUC of 1.",
"   </p>",
"   <p>",
"    As an example, the addition of genetic data to a model for prediction of type 2 diabetes did not improve the model fit and resulted in appropriate reclassification of at most 4 percent of people [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, a high AUC or even an increment in AUC with the addition of genetic variables does not guarantee that the genetic information will be clinically useful. Points along the ROC curve may still correspond to sensitivities and specificities that are too low to be used for screening or prognosis. Furthermore, even if the sensitivity and specificity are high, the usefulness of the genetic variant for classification of risk may be limited due to low allele frequency (ie, only a small proportion of the risk group will be detected or stratified correctly) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A very small p-value does not necessarily translate into a useful clinical marker because effect size (RR or OR) may be small.",
"     </li>",
"     <li>",
"      A high effect size does not necessarily translate into a clinical useful marker because the AUC may be low.",
"     </li>",
"     <li>",
"      A high AUC does not necessarily translate into a clinical useful marker because the combined sensitivity and specificity may be insufficiently high for screening or prognostication.",
"     </li>",
"     <li>",
"      High sensitivity and specificity may not necessarily translate into a clinical useful marker because the allele frequency may be low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These considerations show the difficulty in translating a statistically significant genetic predictor into a clinical useful and accurate clinical classifier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Absolute versus relative effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient's risk of disease is low in the absence of a variant allele, even a 5- or 10-fold increase in risk in the presence of the allele may represent a small absolute increase in risk. Conversely, if the baseline risk is high, a modest increase in relative risk could impact clinical decision making.",
"   </p>",
"   <p>",
"    As an example, Factor V Leiden increases the risk of venous thrombosis by about sixfold [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/61\">",
"     61",
"    </a>",
"    ]. However, the baseline risk of thrombosis in the general population is sufficiently low (about 0.2 percent) that one would not use genotyping as a population screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/62\">",
"     62",
"    </a>",
"    ]. However, the prevalence of Factor V Leiden in patients with venous thrombosis is 12 to 20 percent, and thus testing these patients is worthwhile [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Allele frequency in patient's population",
"    </span>",
"    &nbsp;&mdash;&nbsp;In applying the results, clinicians must consider the likelihood that the particular allele is present in a particular patient. As an example, while factor V Leiden is relatively common in Caucasians (about 1 in 20 individuals are heterozygotes), it is virtually non-existent in Chinese populations. Hence, genotyping for factor V Leiden is unnecessary in a Chinese individual presenting with idiopathic deep venous thrombosis. Allele frequencies for various genes and populations of interest are available in the",
"    <strong>",
"     Al",
"    </strong>",
"    lele",
"    <strong>",
"     fre",
"    </strong>",
"    quency",
"    <strong>",
"     d",
"    </strong>",
"    atabase (ALFRED) or at the HapMap website [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some gene-disease associations may be restricted to a very select subgroup. As an example, BRCA1 was identified in patients with early onset breast cancer who had a strong family history [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/67\">",
"     67",
"    </a>",
"    ]. This group, however, only accounts for approximately 5 percent of all breast cancers. Hence, this genetic association is not worth testing for in those who present with the usual, late-onset breast cancer without a strong family history. However, in certain ancestry groups such as Ashkenazi Jews who have a high prevalence of BRCA1 mutations, testing may be appropriate in women with breast or ovarian cancer (",
"    <a class=\"external\" href=\"file://www.nccn.org/\">",
"     www.nccn.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Patient impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even if the magnitude of the genetic effect is not sufficiently high to be clinically useful in prognostication, it may still be useful clinically in terms of changing risk behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/68\">",
"     68",
"    </a>",
"    ]. Presenting personal genetic information may take advantage of the layman's perception of DNA as their \"life code\" to prompt behavior change.",
"   </p>",
"   <p>",
"    As an example, early evidence suggests that providing information about GST genotypes (affecting nicotine metabolism) may influence smoking cessation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/69\">",
"     69",
"    </a>",
"    ]. This potential benefit should be balanced against the potential worry of knowing that one's risk of health problems years in the future is increased, and the potential for increased insurance premiums or life",
"    <span class=\"nowrap\">",
"     insurance/disability",
"    </span>",
"    denial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2784355\">",
"    <span class=\"h1\">",
"     BIOLOGICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from these potential clinical uses, GWAS results can also shed light on new pathophysiological mechanisms. Principles have been proposed to move beyond identifying single nucleotide polymorphisms (SNPs) to defining their possible functional significance, which might include targeted resequencing, studying the SNP in other populations to further define and narrow linkage disequilibrium, exploring gene transcription functions and epigenetic regulation, and using model systems and cell models to further evaluate the proposed causal variants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3689/abstract/2\">",
"     2",
"    </a>",
"    ]. The challenge of dissecting the correlation between genotype and phenotype will require rigorous evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic association studies seek to identify the genetic component to risk of non-Mendelian complex disorders. The basic assumption regarding genetic determinants of complex disease is that the overall risk of disease is determined by the combination of multiple common genetic variants, each with small effect, and environmental exposures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic association studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The candidate gene approach selects a genetic variant of potential interest and looks for this gene in cases and controls. The genome wide approach looks for an association between a sample of all known variants (eg, hundreds of thousands) and the condition of interest. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic association studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genome-wide association studies have identified some significant polymorphisms (SNPs) associated with disease, but there is still debate about the amount of variance explained by these, ie, missing heritability. Studies should be evaluated for validity, considering potential errors related to phenotyping, genotyping, ancestral differences between cases and controls, and multiple comparators. Hardy-Weinberg allele distribution and consistency between studies are other important considerations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Judging study validity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Questions in applying results of genetic association studies to clinical practice include the effect on predictive power, the magnitude of absolute versus relative effects, generalizability to the given patient, and whether the genetic information will be beneficial to the patient. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Interpreting GWAS results'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/1\">",
"      Visscher PM, Montgomery GW. Genome-wide association studies and human disease: from trickle to flood. JAMA 2009; 302:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/2\">",
"      Freedman ML, Monteiro AN, Gayther SA, et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 2011; 43:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/3\">",
"      Dawn Teare M, Barrett JH. Genetic linkage studies. Lancet 2005; 366:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/4\">",
"      Iyengar SK, Elston RC. The genetic basis of complex traits: rare variants or \"common gene, common disease\"? Methods Mol Biol 2007; 376:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/5\">",
"      Estivill X, Bancells C, Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat 1997; 10:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/6\">",
"      Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/7\">",
"      Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/8\">",
"      Matar&iacute;n M, Brown WM, Scholz S, et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol 2007; 6:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/9\">",
"      International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/10\">",
"      Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/11\">",
"      Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/12\">",
"      Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. N Engl J Med 2007; 357:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/13\">",
"      Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007; 68:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/14\">",
"      Li H, Wetten S, Li L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008; 65:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/15\">",
"      Weedon MN, Lango H, Lindgren CM, et al. Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 2008; 40:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/16\">",
"      Lettre G, Jackson AU, Gieger C, et al. Identification of ten loci associated with height highlights new biological pathways in human growth. Nat Genet 2008; 40:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/17\">",
"      Maher B. Personal genomes: The case of the missing heritability. Nature 2008; 456:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/18\">",
"      Visscher PM, Hill WG, Wray NR. Heritability in the genomics era--concepts and misconceptions. Nat Rev Genet 2008; 9:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/19\">",
"      Wain LV, Armour JA, Tobin MD. Genomic copy number variation, human health, and disease. Lancet 2009; 374:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/20\">",
"      Weiss LA, Shen Y, Korn JM, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008; 358:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/21\">",
"      Conrad DF, Pinto D, Redon R, et al. Origins and functional impact of copy number variation in the human genome. Nature 2010; 464:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/22\">",
"      Wellcome Trust Case Control Consortium, Craddock N, Hurles ME, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 2010; 464:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/23\">",
"      Skinner MK, Manikkam M, Guerrero-Bosagna C. Epigenetic transgenerational actions of environmental factors in disease etiology. Trends Endocrinol Metab 2010; 21:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/24\">",
"      Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet 2010; 42:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/25\">",
"      Yang J, Manolio TA, Pasquale LR, et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet 2011; 43:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/26\">",
"      Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet 2006; 15:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/27\">",
"      Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009; 41:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/28\">",
"      Bouatia-Naji N, Bonnefond A, Cavalcanti-Proen&ccedil;a C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009; 41:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/29\">",
"      Little J, Bradley L, Bray MS, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002; 156:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/30\">",
"      Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE Statement. Ann Intern Med 2009; 150:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/31\">",
"      Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association: B: Are the results of the study valid? JAMA 2009; 301:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/32\">",
"      Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association: C: What are the results and will they help me in caring for my patients? JAMA 2009; 301:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/33\">",
"      Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JP. An empirical evaluation of multifarious outcomes in pharmacogenetics: beta-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenet Genomics 2006; 16:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/34\">",
"      Berkovic SF, Scheffer IE. Genetics of the epilepsies. Epilepsia 2001; 42 Suppl 5:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/35\">",
"      Barnholtz-Sloan JS, McEvoy B, Shriver MD, Rebbeck TR. Ancestry estimation and correction for population stratification in molecular epidemiologic association studies. Cancer Epidemiol Biomarkers Prev 2008; 17:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/36\">",
"      Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/37\">",
"      Kittles RA, Chen W, Panguluri RK, et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 2002; 110:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/38\">",
"      Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/39\">",
"      Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010; 11:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/40\">",
"      Clayton DG, Walker NM, Smyth DJ, et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet 2005; 37:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/41\">",
"      Akey JM, Zhang K, Xiong M, et al. The effect that genotyping errors have on the robustness of common linkage-disequilibrium measures. Am J Hum Genet 2001; 68:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/42\">",
"      Pompanon F, Bonin A, Bellemain E, Taberlet P. Genotyping errors: causes, consequences and solutions. Nat Rev Genet 2005; 6:847.",
"     </a>",
"    </li>",
"    <li>",
"     www.tufts.edu/~mcourt01/Documents/Court%20lab%20-%20HW%20calculator.xls (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     www.oege.org/software/hwe-mr-calc.shtml (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/45\">",
"      Cox DG, Kraft P. Quantification of the power of Hardy-Weinberg equilibrium testing to detect genotyping error. Hum Hered 2006; 61:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/46\">",
"      McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/47\">",
"      Moonesinghe R, Khoury MJ, Liu T, Ioannidis JP. Required sample size and nonreplicability thresholds for heterogeneous genetic associations. Proc Natl Acad Sci U S A 2008; 105:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/48\">",
"      Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/49\">",
"      Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/50\">",
"      Yu W, Wulf A, Yesupriya A, et al. HuGE Watch: tracking trends and patterns of published studies of genetic association and human genome epidemiology in near-real time. Eur J Hum Genet 2008; 16:1155.",
"     </a>",
"    </li>",
"    <li>",
"     www.hugenavigator.net (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/52\">",
"      Salanti G, Southam L, Altshuler D, et al. Underlying genetic models of inheritance in established type 2 diabetes associations. Am J Epidemiol 2009; 170:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/53\">",
"      Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle--will we get our wish? N Engl J Med 2008; 358:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/54\">",
"      Janssens AC, Gwinn M, Bradley LA, et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet 2008; 82:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/55\">",
"      Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/56\">",
"      Janssens AC, van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008; 17:R166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/57\">",
"      McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/58\">",
"      Irwig L, Bossuyt P, Glasziou P, et al. Designing studies to ensure that estimates of test accuracy are transferable. BMJ 2002; 324:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/59\">",
"      Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/60\">",
"      Jakobsdottir J, Gorin MB, Conley YP, et al. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet 2009; 5:e1000337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/61\">",
"      Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/62\">",
"      Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/63\">",
"      Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/64\">",
"      Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503.",
"     </a>",
"    </li>",
"    <li>",
"     The ALlele FREquency Database. Available at: file://alfred.med.yale.edu/alfred/index.asp (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     International HapMap Project. Available at: www.hapmap.org (Accessed on October 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/67\">",
"      Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/68\">",
"      Marteau TM, Lerman C. Genetic risk and behavioural change. BMJ 2001; 322:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3689/abstract/69\">",
"      Hamajima N, Suzuki K, Ito Y, Kondo T. Genotype announcement to Japanese smokers who attended a health checkup examination. J Epidemiol 2006; 16:45.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2902 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-E320E62127-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3689=[""].join("\n");
var outline_f3_38_3689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC ASSOCIATION STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Candidate gene approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genome-wide approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMMON DISEASE-COMMON VARIANT HYPOTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Missing heritability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENOME-WIDE ASSOCIATION STUDIES (GWAS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      JUDGING STUDY VALIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Potential biases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Validity framework",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Phenotyping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ancestry and comorbidities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Accuracy of genotyping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hardy-Weinberg equilibrium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Multiple comparisons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Replication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INTERPRETING GWAS RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Predictive power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Absolute versus relative effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Allele frequency in patient's population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Patient impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2784355\">",
"      BIOLOGICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2902\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2902|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/33/42521\" title=\"figure 1\">",
"      GWAS Stages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/48/18177\" title=\"figure 2\">",
"      Hybridization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/15/30966\" title=\"figure 3\">",
"      Survivor bias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/36/39496\" title=\"figure 4\">",
"      Population stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/56/32653\" title=\"figure 5\">",
"      Sample ROC curve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_38_3690="Various rehabilitation issues in patients treated for cancer";
var content_f3_38_3690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Various rehabilitation issues in patients treated for cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3690/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3690/contributors\">",
"     Vikas Malhotra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3690/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/38/3690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/38/3690/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/38/3690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer face a variety of issues related to rehabilitation. Some are specific to a given tumor (eg, breast, prostate, or head and neck) or a given therapy (eg, creation of an ostomy) while others are related to long-term survival after potentially curative treatment.",
"   </p>",
"   <p>",
"    These issues will be reviewed here. The assessment of functional impairment in patients with cancer and more complete discussions of individual problems are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=see_link\">",
"     \"Functional problems in the patient with cancer\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is the most common cancer in women, mostly occurring in women over age 50. For many affected women, concomitant problems related to aging and menopause will accompany the effects of breast cancer treatment, which is itself associated with a variety of both physical and psychological problems [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The following discussion will emphasize these problems in women although this tumor also occurs in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=see_link\">",
"     \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The disfiguring radical mastectomy (extensive surgery that includes removal of the pectoral muscles) has been largely replaced by modified radical mastectomy or breast conserving surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link\">",
"     \"Mastectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although axillary node dissection is still performed with contemporary surgery, arm and shoulder dysfunction are much less frequent and less severe than occurred historically with more radical breast surgery. Nevertheless, patients still experience psychosocial and cosmetic rehabilitation problems secondary to loss of the breast.",
"   </p>",
"   <p>",
"    Women who receive breast-conserving surgery usually undergo wide excision of the breast tumor and an axillary dissection or sentinel node biopsy. Subsequently, primary radiation therapy is administered to the remaining breast tissue, usually over the course of five to six weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Rationale'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the breast is preserved, these women have upper extremity mobility problems that are identical to those undergoing modified radical mastectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/5,7\">",
"     5,7",
"    </a>",
"    ], and they experience the same range of physical problems (ie, fatigue, limited upper extremity mobility, difficulty lifting, arm weakness, difficulty doing household chores, and arm numbness) as reported after mastectomy.",
"   </p>",
"   <p>",
"    During the year after breast cancer surgery, there are few differences in quality of life, psychosocial adjustment, or performance status in patients receiving mastectomy or breast conservation surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. However, women who receive conservation surgery tend to experience significantly fewer problems with clothing and body image [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;With either type of primary breast cancer surgery, removal of the axillary lymph nodes increases the potential risk of lymphedema. Among the risk factors for lymphedema following breast cancer treatment are the extent of axillary surgery, the use of axillary radiation, and obesity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of lymphedema depends on two factors: (a) not interfering with lymph outflow, by not constricting the arm and by protection from infection, scarring and burns; and (b) limiting capillary filtration by using compression devices when exercising and avoiding vasodilation through heat exposure. Thus, all breast cancer patients should be cautious in avoiding trauma or infection involving the ipsilateral extremity.",
"   </p>",
"   <p>",
"    Once lymphedema is established, it is difficult to treat. There have been few prospective studies to guide optimal management. Conservative management for mild edema includes elevation of the extremity, salt restriction, and an exercise program. Diuretics are of little benefit in chronic lymphedema, and may promote the development of volume depletion. For more severe cases, manual lymphatic drainage, massage therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intermittent pneumatic compression is useful for redistribution of fluid from the extremity. This can be maintained by use of a supportive garment or sleeve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For massive lymphedema which is refractory or whose onset is several years after the primary surgery without obvious trauma, recurrence of the tumor in the axillary area should be excluded by computed tomography or magnetic resonance imaging. In addition, lymphangiosarcoma of the upper extremity is a rare and aggressive tumor which can occur in the setting of postmastectomy lymphedema (Stewart-Treves syndrome), and should be considered in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of physical appearance is very important for a woman who has had a mastectomy. The chest wall is usually quite tender in the immediate postoperative period; as a result, purchase of an external breast prosthesis should be deferred for several weeks. A temporary prosthesis made from soft and lightweight material (cotton, lamb's wool, nylon stockings) can be pinned into the brassiere before a permanent prosthesis is purchased.",
"   </p>",
"   <p>",
"    An American Cancer Society Reach-to-Recovery volunteer will provide a temporary prosthesis when she visits the patient. In addition, the volunteer will often provide a list of stores in the local community that provide fitting and selection of a permanent prosthesis. These permanent breast prostheses come in a wide variety of sizes, weights, and materials, as well as a range of costs. Patients should be encouraged to examine a number of brands before purchasing one. Many specialty shops also offer a range of special garments for use by mastectomees, such as bathing suits and nightgowns.",
"   </p>",
"   <p>",
"    Surgical reconstruction of the breast should be offered to all women who choose or require total mastectomy. Breast reconstruction may require a number of surgical procedures, including reduction mammoplasty for the contralateral breast, and not all women will choose to have additional surgery. Nevertheless, the option of reconstruction should be discussed, preferably prior to the mastectomy (since reconstruction may be undertaken or begun immediately following the mastectomy, see below).",
"   </p>",
"   <p>",
"    The specific reconstructive procedure depends upon the type of primary surgery performed, the condition of the remaining tissue, and the need for postoperative radiation. Skin sparing surgery maximizes breast skin preservation and facilitates immediate reconstruction, resulting in a superior cosmetic appearance without increasing the risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H2464163#H2464163\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Radiation therapy and reconstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediate reconstruction can be performed at the time of the initial mastectomy using a tissue expander, an implant, or a transverse rectus abdominis musculocutaneous (TRAM) flap [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The development of tissue expanders has aided in the breast reconstruction of women whose overlying chest wall skin is relatively taut. In one study of 770 consecutive patients, breast reconstruction using tissue expanders was immediate in 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/13\">",
"     13",
"    </a>",
"    ]. Expansion was successful in the vast majority of patients. Premature removal of the tissue expander was required in only 1.8 percent of patients in this series, most commonly due to infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Psychosocial issues and sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The psychosocial impact of breast cancer and its treatment has been extensively studied. Currently, breast cancer treatment extends over many months beyond surgery due to primary radiation treatment or adjuvant systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recent trends have led to increased patient education and involvement in treatment decisions about their care. As a result, in addition to information regarding the potential toxicities of multimodality therapy, women are frequently given detailed information about prognostic factors and survival statistics. While these trends are generally considered favorable, the dissemination of detailed information, and patient involvement in treatment decisions may contribute to increased anxiety or concerns about recurrence. A number of interventions are available to deal with the side effects of chemotherapy, and support groups or individual psychotherapy are helpful to many patients.",
"   </p>",
"   <p>",
"    Treatment-related fatigue may contribute to a decrease in sexual desire, and result in a decline in the frequency of sexual intercourse. Impaired vaginal lubrication, due to premature ovarian failure or to antiestrogen therapy (especially with aromatase inhibitors) may contribute to low libido and dyspareunia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41496?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\", section on 'Chemotherapy-induced amenorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to concerns over its influence on breast cancer growth, estrogen therapy is generally not prescribed to women with a history of breast cancer. The application of a transdermal testosterone cream did not improve libido in a randomized, placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/17\">",
"     17",
"    </a>",
"    ]. Vaginal lubricating products, which may or may not include hormonal preparations, are available commercially. However, vaginal application of estrogen creams may result in substantial systemic absorption and should probably be avoided in breast cancer survivors.",
"   </p>",
"   <p>",
"    Sexual therapy with a qualified psychotherapist may be useful for those couples in whom a pre-illness sexual pattern has not been reestablished after the cessation of primary cancer treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROSTATE CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is the most common cancer in men, primarily occurring after the age of 50. With the advent of screening with serum prostate specific antigen (PSA), there has been an important stage shift with more men being diagnosed at an earlier stage of disease. Concomitantly, there has been a dramatic increase in the utilization of radical prostatectomy, although primary radiotherapy remains an effective option for men with early stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link\">",
"     \"Screening for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Early stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important sequelae of treatment for early stage prostate cancer include urinary incontinence, rectal urgency, diarrhea (from radiation therapy), and impotence and sexual dysfunction (from both surgery and radiation therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The level of potency after treatment is closely related to the pretreatment sexual functioning and age of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the impact of these treatment-related complications on overall quality of life may not be severe. One study, for example, compared men with localized prostate cancer who had undergone surgery, radiation, or conservative treatment (\"watchful waiting\") to age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/21\">",
"     21",
"    </a>",
"    ]. Despite significantly more sexual and urinary dysfunction in men who had been treated with either surgery or radiation therapy, there were few differences in general dimensions of quality of life and functioning.",
"   </p>",
"   <p>",
"    With the advent of new therapies for erectile dysfunction (pharmaceutical and mechanical), many of these men may be able to have erections sufficient for sexual intercourse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H24077796#H24077796\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Impotence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An open discussion regarding both the level and importance of sexual functioning with the patient and his partner is warranted prior to the treatment of prostate cancer, and then in follow-up after treatment has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Advanced stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen ablative therapies (orchiectomy, gonadotropin-releasing hormone analogs, and antiandrogens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    ) are effective for the initial treatment of metastatic prostate cancer. Although these therapies reliably diminish disease burden, they can result in decreased libido, impotence, fatigue, loss of bone and lean body mass, and decreased muscle strength. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link\">",
"     \"Side effects of androgen deprivation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative therapies such as intermittent rather than continuous androgen deprivation or antiandrogen monotherapy may control disease while allowing men to maintain their sexual capacity, at least in the intertreatment intervals. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=see_link\">",
"     \"Initial hormone therapy for metastatic prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium and vitamin D supplementation should be considered to diminish the osteopenic effects of long-term androgen ablation, and bisphosphonates may provide benefit for those with established bone metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link\">",
"     \"Side effects of androgen deprivation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=see_link&amp;anchor=H19250956#H19250956\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Osteoclast inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of regular exercise in maintaining functional capacity was shown in a randomized trial, in which 155 men undergoing initial androgen deprivation therapy were randomly assigned to 12 weeks of resistance exercise performed three times per week, or no exercise. The group receiving resistance exercise had significantly better fatigue and quality of life scores, as well as improved overall muscular fitness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEAD AND NECK CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with head and neck cancer share a common set of problems despite having a wide variety of specific cancer sites within this anatomic region:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although surgery and radiotherapy are the mainstays of treatment, chemotherapy is being used more frequently both concurrently with radiation therapy, and in the neoadjuvant setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=see_link\">",
"       \"Overview of head and neck cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28649?source=see_link\">",
"       \"Methods to overcome radiation resistance in head and neck cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many head and neck cancers are associated with tobacco and alcohol abuse by the patient. These habits are associated with a variety of complex psychosocial problems related to addiction and lack of social support. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"       \"Epidemiology and risk factors for head and neck cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=see_link\">",
"       \"Quality of life in head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Difficulties with speech and eating are common, both as a direct result of the tumor and as a consequence of therapy. Particular concern should be paid to dental evaluation, nutritional issues, and speech and swallowing rehabilitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dental issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment dental evaluation is important in patients receiving radiotherapy because post-treatment xerostomia can accelerate the development or progression of dental caries. The approach to this problem must take into consideration the possible development of osteoradionecrosis as a late complication of radiation treatment; this process is hastened by trauma to the irradiated bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For this reason, all dental extractions should be completed prior to the initiation of radiation and careful oral hygiene should be maintained during and after radiation treatment. Compliance with oral hygiene regimens must be emphasized as a preventive strategy. Dental implants may be considered although the soft tissue complication rate is higher than in nonirradiated bone (27 versus 8 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nutritional issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of adequate nutrition is a significant problem for many patients with head and neck cancer. Consultation with a dietitian is frequently helpful in the selection of foods that do not require chewing and can be easily swallowed. Liquid nutritional supplements play an important role in the rehabilitation of these patients, and nasogastric feedings may be required if oral intake is inadequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=see_link\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radical neck dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with head and neck cancer require a radical neck dissection as part of their definitive surgical treatment because of the presence of clinical nodal disease or a high expectation of nodal disease.",
"   </p>",
"   <p>",
"    The accessory nerve is usually severed as part of this procedure, leading to denervation of the trapezius muscle. This results in serious shoulder dysfunction that is both physical and cosmetic. The trapezius muscle is responsible for upward rotation of the shoulder during abduction and flexion, and in addition is the major stabilizer of the scapula. The loss of this muscle leads to shoulder malalignment and motor dysfunction, resulting in an inability to push, lift, or carry heavy objects. Shoulder range of motion is usually limited and painful. The degree of disability is variable and dependent upon the degree of innervation of the trapezius muscle by subfascial branches of the cervical plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of cancer pain syndromes\", section on 'Postsurgical pain syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical therapy interventions are available to address these problems and should be an integral part of the rehabilitation of these patients. If motor dysfunction results from the radical neck dissection, then range of motion exercises directed by a physical therapist can facilitate the recovery process. It is also possible to reinnervate the muscle by anastomosing the subfascial branch of the deep cervical plexus to the distal stump of the accessory nerve, using microsurgical techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surgical restoration of physical defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cosmetic restoration of physical defects resulting from surgery to parts of the face or oropharynx (the nose, orbit, maxilla, or mandible) is an important issue for patients with head and neck cancer. Maxillofacial prosthodontists are the subspecialists who design the individualized prosthetic devices for these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/45/8919?source=see_link\">",
"     \"Management of acquired maxillary defects: Prosthetic rehabilitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These prostheses are used to restore both function and cosmesis. Without cosmetic rehabilitation, there may be continued and worsening psychological distress. Preparation of the maxillofacial prosthesis is a multistep process with pretreatment evaluation and several subsequent evaluations in the post-treatment period. Final prosthesis preparation does not occur until complete healing of the involved tissues many months after diagnosis, surgery, and radiation treatment. In the interim, a temporary prosthesis may be utilized. Patients are in considerable need of psychological support during the period of adaptation to their physical loss, especially prior to completion of surgical reconstruction or prosthetic restoration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Speech restoration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of speech is an additional area of particular concern for patients with head and neck cancer. Treatment of tumors of the nose, mouth, pharynx, and larynx cause a variety of speech deficits. At the extreme is the patient with total laryngectomy who will need training in esophageal speech or in utilizing one of several prosthetic devices that permit transmission of sounds generated in the neck to the oral cavity to produce audible speech. Laryngectomee support groups can be found in many communities and can serve as an invaluable resource to patients and their families. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=see_link\">",
"     \"Alaryngeal speech rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who undergo partial or total glossectomy are also candidates for speech therapy intervention and may require prosthetic devices to assist in the speech rehabilitation process. There are many psychological consequences of the loss of speech that must be dealt with preoperatively as well as in the postoperative period. Speech articulation may be markedly improved through the use of a myocutaneous flap reconstruction in patients with partial glossectomies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PATIENTS WITH OSTOMIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who require an ostomy as part of their cancer treatment represent another group with special rehabilitation needs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/28\">",
"     28",
"    </a>",
"    ]. These include patients with rectal or sigmoid colon cancers and patients with a variety of pelvic tumors (bladder, cervix, uterus) for whom a urinary diversion is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link\">",
"     \"Management of patients with a colostomy or ileostomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32298?source=see_link\">",
"     \"Urinary diversion and reconstruction following cystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An enterostomal therapist should see the patient prior to surgery to provide information and reassurance about the ostomy, its function, and care. In addition, the therapist can aid the surgeon in identifying the best location for the stoma to ensure that it can be easily managed by the patient, adequately supported, and away from the beltline or body folds.",
"   </p>",
"   <p>",
"    In the immediate postoperative period, the enterostomal therapist begins direct teaching with the patient on the care of the stoma and the use of appliances. The patient must be encouraged to view the stoma site as well as touch it in order to develop independence and self-confidence regarding self-care. If the patient has difficulty adjusting to the stoma, the emotional response can impair the teaching process. Periodic home-care visits by a stomal therapist after discharge from the hospital will facilitate the recovery process and engender patient confidence. Meticulous skin care should be emphasized and monitored.",
"   </p>",
"   <p>",
"    During the early postoperative period, the patient and family members can benefit from peer support such as that available through the United Ostomy Association (",
"    <a class=\"external\" href=\"file://www.uoa.org/\">",
"     www.uoa.org",
"    </a>",
"    ). A volunteer visitor with an ostomy can provide reassurance as a living example of an individual who has successfully adapted to life with a stoma. In addition, many local chapters of the organization have regular support groups and periodicals that are helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link&amp;anchor=H39#H39\">",
"     \"Management of patients with a colostomy or ileostomy\", section on 'Resources'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the months following surgery, the patient should be encouraged to resume usual activities, including sexual activity and work. Sexual rehabilitation of the ostomate must address the physical loss of pelvic organs, the presence of the stoma or appliance, and the psychologic impact of the changes in personal bodily function related to elimination. Preoperative discussion of the sexual impact of treatment is extremely important. The presence of an ostomy should",
"    <strong>",
"     not",
"    </strong>",
"    be a deterrent to successful pregnancy and delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EXTREMITY AMPUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremity amputations that are performed because of a cancer lead to a wide range of physical and psychological rehabilitation problems. The functional impairment relates to the location of the primary tumor and the extent of the amputation. Unlike amputations performed for benign conditions, amputations for cancer may be radical and include such procedures as a hemipelvectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A preoperative assessment should be performed to prepare the prostheses and to orient patients to the postoperative rehabilitation program. Crutch walking can be introduced at this time when balance is better and there is no pain. Rigid dressings are recommended in the postoperative period to decrease pain and the potential for phantom limb sensation.",
"   </p>",
"   <p>",
"    A physical therapy program should be encouraged in the postoperative period to maintain strength and prevent contractures. The prosthesis cannot be used until the stump shrinkage is complete, and at that time the patient will need gait training and assistance in ambulation.",
"   </p>",
"   <p>",
"    Bone and soft tissue cancers are primarily tumors of children, adolescents, and young adults. Such patients can be especially vulnerable to psychological problems [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Education is usually interrupted, particularly if the patient requires adjuvant chemotherapy, and recreational and social activities may require modification. Counseling should be offered to the patient and family to deal with the disruption caused by the cancer treatment and with the long-term problems of physical and vocational rehabilitation.",
"   </p>",
"   <p>",
"    Phantom limb pain is a frequent complication of limb amputation, particularly low extremity amputation. Besides having a negative effect on quality of life, patients suffering from this condition often make heavy use of the medical system. Phantom limb pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of cancer pain syndromes\", section on 'Pain and phantom sensation after limb amputation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     REHABILITATION PROBLEMS OF LONG-TERM SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing population of long-term survivors of cancer treatment, ranging from survivors of pediatric cancers to young adults with Hodgkin lymphoma or testicular cancer to older adults with breast or colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These gains in survivorship have been accomplished through increasingly complex primary treatments, usually combining surgery. There are possible long-term sequelae from each of these treatments and there can be potentiation of toxicities when treatments are combined [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Radiation damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation injury to normal tissues can be relatively mild during acute treatment, but may result in progressive chronic injury over the ensuing years. The lungs, heart, intestines, and soft tissues are most likely to manifest these changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, radiation effects on the long bones and spine in children can lead to growth retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/35\">",
"     35",
"    </a>",
"    ]. The toxicity of radiation is potentiated by several chemotherapeutic agents that either act as radiation sensitizers or which by themselves can produce organ damage (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    with or without tocopherol (vitamin E) may be useful in the treatment of radiation-induced soft tissue fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=see_link\">",
"     \"Clinical manifestations and treatment of radiation-induced fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation-induced second malignancies are a major concern, particularly among individuals treated at a young age for a soft tissue or bone sarcoma. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Second malignancies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Delayed effects from primary curative therapy may not become manifest until many years after primary treatment. As an example, radiation injury to the brain and central nervous system (CNS) occurs in children receiving CNS prophylaxis for acute leukemia and craniospinal irradiation for primary CNS tumors. While this treatment has greatly lengthened survival, this benefit occurs at the cost of serious cognitive disability and learning disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H20#H20\">",
"     \"Complications of cranial irradiation\", section on 'Neurocognitive effects in adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an attempt to minimize neurologic injury, chemotherapy has taken on a more prominent role in the therapy of some pediatric tumors. Newer treatment protocols are being devised in an attempt to modify toxicity without the sacrificing the likelihood of cure. However, more intensive chemotherapy regimens may be associated with an increased risk of second malignancies (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Second malignancies'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=see_link\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility is an increasingly important complication of cancer therapy as young patients are more likely to be cured of their cancers (eg, leukemia, Hodgkin lymphoma, germ cell tumors) than are older adults. Several chemotherapy drugs (primarily alkylating agents) and radiation therapy are directly toxic to normal gonadal tissue, and often little can be done to eliminate the use of these treatments if cure is the goal of therapy.",
"   </p>",
"   <p>",
"    Potential infertility should be discussed with the patient prior to the initiation of treatment. Unfortunately, fewer than one-half of oncologists bring up this topic [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/37\">",
"     37",
"    </a>",
"    ], despite the prevalence of anxiety related to fertility issues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"     \"Effects of cytotoxic agents on gonadal function in adult men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relatively little information is available about prevention of gonadal dysfunction during cancer therapy. Possible approaches to preserving the potential for future fertility include induction of gonadal quiescence and preservation of sperm or oocytes by freezing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men, it is possible to make use of sperm banking. However, in one series, only 24 percent of men banked sperm despite 51 percent desiring future paternity; lack of information was the most common reason given for the failure to bank sperm [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/41\">",
"       41",
"      </a>",
"      ]. A complicating issue is that many men with newly diagnosed cancer are azoospermic secondary to the acute illness (eg, testicular cancer) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=see_link\">",
"       \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      This is less of a consideration at present because of the availability of intracytoplasmic sperm injection (ICSI). A survey of 46 oncologists who counseled patients regarding pretherapy cryopreservation found that only about one in four men chose to cryopreserve sperm; however, only 26 percent of the oncologists knew about ICSI [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=see_link\">",
"       \"Intracytoplasmic sperm injection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"       \"Treatment of male infertility\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In women, oophoropexy is recommended in those receiving radiation treatment for Hodgkin lymphoma to decrease the dose of radiation to the ovaries [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/43\">",
"       43",
"      </a>",
"      ]. In postpubertal females, stimulation of the ovaries with exogenous gonadotropins and retrieval of mature oocytes for cryopreservation has had limited success. Orthotopic transplantation of cryopreserved ovarian tissue is an experimental procedure. Cryopreservation of embryos is possible [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link&amp;anchor=H6#H6\">",
"       \"Ovarian failure due to anticancer drugs and radiation\", section on 'Prevention of ovarian failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H2#H2\">",
"       \"Oophorectomy and ovarian cystectomy\", section on 'Oophorectomy versus cystectomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"       \"Overview of fertility and pregnancy in cancer survivors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The contemporary substitution of ABVD for MOPP therapy in the treatment of Hodgkin lymphoma should reduce gonadal toxicity for both sexes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H9#H9\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'ABVD toxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the increasing success in treating many cancers (particularly hematologic malignancies and pediatric sarcomas) has come the development of late complications, with second malignancies being the most serious. As an example, in patients treated for Hodgkin lymphoma, there is an excess of acute nonlymphocytic leukemia and non-Hodgkin lymphoma in patients treated with chemotherapy and radiotherapy and solid tumors in patients treated with radiotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. In one series of 1507 patients, for example, the actuarial 15-year risk of second malignancy was 17.6 percent: 13.2 percent solid tumors; 3.3 percent leukemia; and 1.6 percent NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second malignancies are a major concern among individuals treated with radiation for a sarcoma of the bone or soft tissue, particularly at a young age. In children, this has prompted the development of alternative treatment strategies that do not contain radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link\">",
"     \"Radiation therapy for Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link&amp;anchor=H27#H27\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'RT and chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second malignancies can also complicate the treatment of brain tumors in children, breast cancer in women, and high dose chemotherapy with hematopoietic cell transplantation for hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/38/3690/abstract/36,49\">",
"     36,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=see_link\">",
"     \"Malignancy after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=see_link&amp;anchor=H949706103#H949706103\">",
"     \"Complications of breast and chest wall irradiation for early stage breast cancer\", section on 'Secondary malignancies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, concerns have been raised that the increasing use of diagnostic imaging with higher-radiation techniques (eg, spiral CT) for post-treatment surveillance is also contributing to excess radiation exposure and a higher risk for second malignancies. Care should be taken to limit the number of unnecessary scans, particularly in younger individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cardiovascular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some chemotherapeutic agents have the potential to damage the heart muscle, while others cause arrhythmias or coronary artery vasospasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most prominent among the potentially cardiotoxic drugs are the anthracyclines, which induce a dose-dependent cardiomyopathy. Approximately 5 percent of patients who receive a cumulative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    dose 500 to 550",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    will develop heart failure, and the risk increases with higher cumulative doses. Coexisting cardiac disease, hypertension, advanced age, and concomitant thoracic radiation therapy may hasten the onset of heart failure at lower cumulative doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anthracycline-induced heart failure is not readily reversible; mortality is as high as 50 percent. Thus, prevention is the best approach. The various approaches to minimizing this complication are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H15#H15\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Approaches for reducing the risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9895427\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cancer face a variety of issues related to rehabilitation, many of which are specific to a given tumor (eg, breast, prostate, or head and neck) or a given therapy (eg, creation of an ostomy).",
"     </li>",
"     <li>",
"      Rehabilitation issues among women treated for breast cancer may include lymphedema, body image issues, and sexual dysfunction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important sequelae of treatment for early stage prostate cancer include urinary incontinence, rectal urgency, diarrhea (from radiation therapy), and sexual dysfunction. For men treated for advanced disease, androgen deprivation therapy can result in decreased libido, impotence, fatigue, loss of bone and lean body mass, and decreased muscle strength. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prostate cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with head and neck cancer share a common set of problems despite having a wide variety of specific cancer sites within this anatomic region; difficulties with speech and eating are common, both as a direct result of the tumor and as a consequence of therapy. Particular concern should be paid to dental evaluation, nutritional issues, and speech and swallowing rehabilitation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Head and neck cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who require an ostomy as part of their cancer treatment represent a group with special rehabilitation needs. An enterostomal therapist should see the patient prior to surgery to provide information and reassurance about the ostomy, its function, and care. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Patients with ostomies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extremity amputations that are performed because of a cancer lead to a wide range of physical and psychological rehabilitation problems. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Extremity amputations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a growing population of long-term survivors of cancer treatment. Gains in survivorship have been accomplished through increasingly complex primary treatments, often combining surgery, radiation therapy, and chemotherapy. There are possible long-term sequelae from each of these treatments, including the effects of radiation damage to normal tissues, infertility, second malignancies, and cardiovascular, pulmonary, and neurologic toxicity. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Rehabilitation problems of long-term survivors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/1\">",
"      Meyerowitz BE. Psychosocial correlates of breast cancer and its treatments. Psychol Bull 1980; 87:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/2\">",
"      Lewis FM, Bloom JR. Psychosocial adjustment to breast cancer: a review of selected literature. Int J Psychiatry Med 1978; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/3\">",
"      Holland JC, Jacobs E. Psychiatric sequelae following surgical treatment of breast cancer. Adv Psychosom Med 1986; 15:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/4\">",
"      Schain W, Edwards BK, Gorrell CR, et al. Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation. Breast Cancer Res Treat 1983; 3:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/5\">",
"      Ganz PA, Schag CC, Polinsky ML, et al. Rehabilitation needs and breast cancer: the first month after primary therapy. Breast Cancer Res Treat 1987; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/6\">",
"      Schag CA, Ganz PA, Polinsky ML, et al. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 1993; 11:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/7\">",
"      Shimozuma K, Ganz PA, Petersen L, Hirji K. Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery. Breast Cancer Res Treat 1999; 56:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/8\">",
"      Ganz PA, Schag AC, Lee JJ, et al. Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? Cancer 1992; 69:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/9\">",
"      Kiebert GM, de Haes JC, van de Velde CJ. The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol 1991; 9:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/10\">",
"      Wolberg WH, Romsaas EP, Tanner MA, Malec JF. Psychosexual adaptation to breast cancer surgery. Cancer 1989; 63:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/11\">",
"      Cozen W, Bernstein L, Wang F, et al. The risk of angiosarcoma following primary breast cancer. Br J Cancer 1999; 81:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/12\">",
"      Simmons RM, Fish SK, Gayle L, et al. Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. Ann Surg Oncol 1999; 6:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/13\">",
"      Disa JJ, Ad-El DD, Cohen SM, et al. The premature removal of tissue expanders in breast reconstruction. Plast Reconstr Surg 1999; 104:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/14\">",
"      Watier E, Lev&ecirc;que J, Pioud R, et al. Immediate breast reconstruction with deepidermalized transverse rectus abdominis musculocutaneous flap after skin-sparing mastectomy. Eur J Obstet Gynecol Reprod Biol 1999; 84:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/15\">",
"      Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998; 16:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/16\">",
"      Schover LR. The impact of breast cancer on sexuality, body image, and intimate relationships. CA Cancer J Clin 1991; 41:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/17\">",
"      Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst 2007; 99:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/18\">",
"      Litwin MS, Flanders SC, Pasta DJ, et al. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999; 54:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/19\">",
"      McCammon KA, Kolm P, Main B, Schellhammer PF. Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 1999; 54:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/20\">",
"      Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/21\">",
"      Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/22\">",
"      Turner SL, Adams K, Bull CA, Berry MP. Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology 1999; 54:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/23\">",
"      Werkmeister R, Szulczewski D, Walteros-Benz P, Joos U. Rehabilitation with dental implants of oral cancer patients. J Craniomaxillofac Surg 1999; 27:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/24\">",
"      Krause HR. Shoulder-arm-syndrome after radical neck dissection: its relation with the innervation of the trapezius muscle. Int J Oral Maxillofac Surg 1992; 21:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/25\">",
"      Erisen L, Basel B, Irdesel J, et al. Shoulder function after accessory nerve-sparing neck dissections. Head Neck 2004; 26:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/26\">",
"      Krause HR. Reinnervation of the trapezius muscle after radical neck dissection. J Craniomaxillofac Surg 1994; 22:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/27\">",
"      Lyos AT, Evans GR, Perez D, Schusterman MA. Tongue reconstruction: outcomes with the rectus abdominis flap. Plast Reconstr Surg 1999; 103:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/28\">",
"      Hurny C, Holland J. Psychosocial sequelae of ostomies in cancer patients. CA Cancer J Clin 1985; 35:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/29\">",
"      Van Horn C, Barrett P. Pregnancy, delivery, and postpartum experiences of fifty-four women with ostomies. J Wound Ostomy Continence Nurs 1997; 24:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/30\">",
"      Tebbi CK, Petrilli AS, Richards ME. Adjustment to amputation among adolescent oncology patients. Am J Pediatr Hematol Oncol 1989; 11:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/31\">",
"      Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med 1985; 313:270.",
"     </a>",
"    </li>",
"    <li>",
"     Koocher GP, O'Malley JE. The Damocles syndrome: Psychosocial consequences of surviving childhood cancer, McGraw-Hill, New York 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/33\">",
"      Loescher LJ, Welch-McCaffrey D, Leigh SA, et al. Surviving adult cancers. Part 1: Physiologic effects. Ann Intern Med 1989; 111:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/34\">",
"      Welch-McCaffrey D, Hoffman B, Leigh SA, et al. Surviving adult cancers. Part 2: Psychosocial implications. Ann Intern Med 1989; 111:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/35\">",
"      Willman KY, Cox RS, Donaldson SS. Radiation induced height impairment in pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994; 28:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/36\">",
"      Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 1998; 44:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/37\">",
"      Schover LR, Brey K, Lichtin A, et al. Oncologists' attitudes and practices regarding banking sperm before cancer treatment. J Clin Oncol 2002; 20:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/38\">",
"      Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997; 126:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/39\">",
"      Koeppel KM. Sperm banking and patients with cancer. Issues concerning patients and healthcare professionals. Cancer Nurs 1995; 18:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/40\">",
"      Pfeifer SM, Coutifaris C. Reproductive technologies 1998: options available for the cancer patient. Med Pediatr Oncol 1999; 33:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/41\">",
"      Schover LR, Brey K, Lichtin A, et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002; 20:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/42\">",
"      Zapzalka DM, Redmon JB, Pryor JL. A survey of oncologists regarding sperm cryopreservation and assisted reproductive techniques for male cancer patients. Cancer 1999; 86:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/43\">",
"      Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer 1999; 86:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/44\">",
"      Donnez J, Bassil S. Indications for cryopreservation of ovarian tissue. Hum Reprod Update 1998; 4:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/45\">",
"      Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/46\">",
"      Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/47\">",
"      Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/48\">",
"      Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992; 3 Suppl 4:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/38/3690/abstract/49\">",
"      Kolb HJ, Soci&eacute; G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131:738.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2827 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-197.136.42.3-3245C6EF35-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3690=[""].join("\n");
var outline_f3_38_3690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9895427\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lymphedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Psychosocial issues and sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROSTATE CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Early stage disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Advanced stage disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEAD AND NECK CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dental issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nutritional issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radical neck dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surgical restoration of physical defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Speech restoration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PATIENTS WITH OSTOMIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EXTREMITY AMPUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      REHABILITATION PROBLEMS OF LONG-TERM SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Radiation damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cardiovascular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9895427\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17129?source=related_link\">",
"      Clinical manifestations and treatment of radiation-induced fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=related_link\">",
"      Complications of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=related_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=related_link\">",
"      Functional problems in the patient with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1353?source=related_link\">",
"      Initial hormone therapy for metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15546?source=related_link\">",
"      Intracytoplasmic sperm injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=related_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/45/8919?source=related_link\">",
"      Management of acquired maxillary defects: Prosthetic rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28649?source=related_link\">",
"      Methods to overcome radiation resistance in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=related_link\">",
"      Overview of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=related_link\">",
"      Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=related_link\">",
"      Quality of life in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=related_link\">",
"      Radiation therapy for Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/34/32298?source=related_link\">",
"      Urinary diversion and reconstruction following cystectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_38_3691="Causes false positive pheo";
var content_f3_38_3691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications that may increase measured levels of catecholamines and metanephrines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levodopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs containing adrenergic receptor agonists (eg, decongestants)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphetamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buspirone and most psychoactive agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prochlorperazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reserpine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Withdrawal from clonidine and other drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetaminophen (may increase measured levels of fractionated plasma metanephrines in some assays)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3691=[""].join("\n");
var outline_f3_38_3691=null;
var title_f3_38_3692="Interpretation of DLCO";
var content_f3_38_3692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpretation of diffusing capacity of the lungs for carbon monoxide (DLCO)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased DLCO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycythemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left-to-right intracardiac shunting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild left heart failure - increased pulmonary capillary blood volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise just prior to the test - increased cardiac output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low DLCO with normal spirometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia - mild decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary vascular disease - mild to severe decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early interstitial lung disease - mild to moderate decrease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low DLCO with obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emphysema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphangioleiomyomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low DLCO with restriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial lung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia - reduces DLCO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carboxyhemoglobin - reduces DLCO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altitude - increases DLCO",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3692=[""].join("\n");
var outline_f3_38_3692=null;
var title_f3_38_3693="Parapneumonic effusion drainage";
var content_f3_38_3693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Categorizing risk for poor outcome in patients with parapneumonic effusions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Pleural space anatomy",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Pleural fluid bacteriology",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Pleural fluid chemistry*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of poor outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drainage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A0",
"       </td>",
"       <td>",
"        Minimal, free flowing (&lt;10 mm on lat decub film)&yen;",
"       </td>",
"       <td>",
"        AND",
"       </td>",
"       <td>",
"        Bx",
"       </td>",
"       <td>",
"        Culture and Gram AND stain results unknown",
"       </td>",
"       <td>",
"        AND",
"       </td>",
"       <td>",
"        Cx",
"       </td>",
"       <td>",
"        pH unknown",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Very low",
"       </td>",
"       <td>",
"        No**",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A1",
"       </td>",
"       <td>",
"        Small to moderate free flowing effusion (&gt;10 mm and &lt;1/2 hemithorax)",
"       </td>",
"       <td>",
"        AND",
"       </td>",
"       <td>",
"        B0",
"       </td>",
"       <td>",
"        Neg culture and Gram stain&yen;&yen;",
"       </td>",
"       <td>",
"        AND",
"       </td>",
"       <td>",
"        C0",
"       </td>",
"       <td>",
"        pH &ge;7.20",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        No&dagger;&dagger;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        A2",
"       </td>",
"       <td rowspan=\"2\">",
"        Large, free flowing (&ge;1/2 hemithorax)***, loculated effusion&dagger;&dagger;&dagger;, or effusion with thickened parietal pleura&yen;&yen;&yen;",
"       </td>",
"       <td rowspan=\"2\">",
"        OR",
"       </td>",
"       <td>",
"        B1",
"       </td>",
"       <td>",
"        Positive culture or Gram stain",
"       </td>",
"       <td rowspan=\"2\">",
"        OR",
"       </td>",
"       <td rowspan=\"2\">",
"        C1",
"       </td>",
"       <td rowspan=\"2\">",
"        pH &lt;7.20",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B2",
"       </td>",
"       <td>",
"        &nbsp;pus",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * pH is the preferred pleural fluid chemistry test, and pH must be determined by a blood gas analyzer. If a blood gas analyzer is not available, pleural fluid glucose should be used (P0 = glucose &ge;60 mg/dL; P1 = glucose &lt;60 mg/dL). The expert panel cautions that the clinical utility and decision thresholds for pH and glucose have not been well-established.",
"     <br>",
"      &yen; Clinical experience indicates that effusions of this size do not require thoracentesis for evaluation, but will resolve.",
"      <br>",
"       ** If thoracentesis were performed in a patient with A0 category pleural anatomy and P1 or B1 status found, clinical experience suggests that the P1 or B1 findings might be false-positive. Repeat thoracentesis should be considered if effusion enlarges and/or clinical condition deteriorates.",
"       <br>",
"        &dagger;&dagger; If clinical condition deteriorates, repeat thoracentesis and drainage should be considered.",
"        <br>",
"         &yen;&yen; Regardless of prior antibiotic use.",
"         <br>",
"          *** Larger effusions are more resistant to effective drainage, possibly because of the increased likelihood that large effusions will also be loculated.",
"          <br>",
"           &dagger;&dagger;&dagger; Pleural loculations suggest a worse prognosis.",
"           <br>",
"            &yen;&yen;&yen; Thickened parietal pleura on contrast-enhanced CT suggests presence of empyema.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Colice, GL, Curtis, A, Deslauriers, J, et al, Chest 2000; 118:1158.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3693=[""].join("\n");
var outline_f3_38_3693=null;
var title_f3_38_3694="Endoprosthesis cholangioscopy";
var content_f3_38_3694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Percutaneous cholangioscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    End of a broken endoprosthesis seen through a cholangioscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jurgen F Riemann, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3694=[""].join("\n");
var outline_f3_38_3694=null;
var title_f3_38_3695="Stage-based survival in patients with RCC";
var content_f3_38_3695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Stage-based survival in patients with renal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 442px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_38_3695=[""].join("\n");
var outline_f3_38_3695=null;
